Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:ssspta1623hrr

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

```
* * * * * * * * * Welcome to STN International
```

```
Web Page URLs for STN Seminar Schedule - N. America
NEWS
     1
                 "Ask CAS" for self-help around the clock
NEWS
                 Source of Registration (SR) information in REGISTRY updated
NEWS
         JAN 27
                 and searchable
                 A new search aid, the Company Name Thesaurus, available in
NEWS
         JAN 27
                 CA/CAplus
                 German (DE) application and patent publication number format
         FEB 05
NEWS
     5
                 changes
                 MEDLINE and LMEDLINE reloaded
NEWS
        MAR 03
     6
                 MEDLINE file segment of TOXCENTER reloaded
        MAR 03
NEWS
     7
                 FRANCEPAT now available on STN
        MAR 03
NEWS
     8
                 Pharmaceutical Substances (PS) now available on STN
        MAR 29
NEWS
     9
        MAR 29
                 WPIFV now available on STN
NEWS 10
                 New monthly current-awareness alert (SDI) frequency in RAPRA
NEWS 11
        MAR 29
                 PROMT: New display field available
         APR 26
NEWS 12
                 IFIPAT/IFIUDB/IFICDB: New super search and display field
NEWS 13
         APR 26
                 available
                 LITALERT now available on STN
         APR 26
NEWS 14
                 NLDB: New search and display fields available
         APR 27
NEWS 15
                 PROUSDDR now available on STN
NEWS 16
         May 10
                 PROUSDDR: One FREE connect hour, per account, in both May
         May 19
NEWS 17
                 and June 2004
                 EXTEND option available in structure searching
         May 12
NEWS 18
                 Polymer links for the POLYLINK command completed in REGISTRY
NEWS 19
         May 12
         May 17
                 FRFULL now available on STN
NEWS 20
              MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT
NEWS EXPRESS
              MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
              AND CURRENT DISCOVER FILE IS DATED 26 APRIL 2004
              STN Operating Hours Plus Help Desk Availability
NEWS HOURS
              General Internet Information
NEWS INTER
              Welcome Banner and News Items
NEWS LOGIN
              Direct Dial and Telecommunication Network Access to STN
NEWS PHONE
              CAS World Wide Web Site (general information)
NEWS WWW
```

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 15:30:31 ON 26 MAY 2004

=> file registry
COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 0.21 0.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 15:30:42 ON 26 MAY 2004 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 25 MAY 2004 HIGHEST RN 685826-98-6 DICTIONARY FILE UPDATES: 25 MAY 2004 HIGHEST RN 685826-98-6

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at: http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\STNEXP4\QUERIES\10660439.str

L1 STRUCTURE UPLOADED

=> d 11
L1 HAS NO ANSWERS
L1 STR

OPPO

Option

Structure attributes must be viewed using STN Express query preparation.

FULL SEARCH INITIATED 15:31:03 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 164 TO ITERATE

100.0% PROCESSED 164 ITERATIONS SEARCH TIME: 00.00.01

85 ANSWERS

L2 85 SEA SSS FUL L1

=> d 1-85 12

L2 ANSWER 1 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN

RN 556808-14-1 REGISTRY

CN Phosphoric acid, mono(3-chlorophenyl) mono[2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl] ester, ammonium salt (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C24 H24 Cl O8 P . H3 N

SR CA

LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER

DT.CA CAplus document type: Journal

RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation)

Double bond geometry as shown.

● NH<sub>3</sub>

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 2 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN

RN 556808-13-0 REGISTRY

CN Phosphoric acid, monocyclohexyl mono[2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl] ester, ammonium salt (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C24 H31 O8 P . H3 N

SR CA

LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER

DT.CA CAplus document type: Journal

RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation)

# ● NH3

1 REFERENCES IN FILE CA (1907 TO DATE) 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 3 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN

RN 556808-12-9 REGISTRY

CN Phosphoric acid, mono[2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl]ethenyl]phenyl] mono(2,2,2-trifluoroethyl) ester, ammonium salt (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C20 H22 F3 O8 P . H3 N

SR CA

LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER

DT.CA CAplus document type: Journal

RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation)

Double bond geometry as shown.

$$MeO$$
 $T$ 
 $OMe$ 
 $OMe$ 
 $OMe$ 
 $OMe$ 

### NH3

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 4 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN

RN 556808-11-8 REGISTRY

CN Phosphoric acid, dibutyl 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl ester (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C26 H37 O8 P

SR CA

LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER

DT.CA CAplus document type: Journal

RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation)

Double bond geometry as shown.

#### \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 5 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN

RN 556808-10-7 REGISTRY

CN Phosphoric acid, diethyl 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl ester (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C22 H29 O8 P

SR CA

LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER

DT.CA CAplus document type: Journal

RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation)

Double bond geometry as shown.

# \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

- 1 REFERENCES IN FILE CA (1907 TO DATE)
- 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)
- L2 ANSWER 6 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
- RN 556808-09-4 REGISTRY
- CN Phosphoric acid, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]pheny l dimethyl ester (9CI) (CA INDEX NAME)
- FS STEREOSEARCH

MF C20 H25 O8 P

SR CA

LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER

DT.CA CAplus document type: Journal

RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation)

Double bond geometry as shown.

# \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 7 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN

RN 519060-38-9 REGISTRY

CN 1,4-Benzenediol, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, bis(dihydrogen phosphate), tetrasodium salt (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C18 H22 O12 P2 . 4 Na

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

DT.CA CAplus document type: Patent

RL.P Roles from patents: BIOL (Biological study); USES (Uses)

Double bond geometry as shown.

$$\begin{array}{c|c} \text{OPO}_3\text{H}_2 \\ \hline \\ \text{OPO}_3\text{H}_2 \\ \hline \end{array} \begin{array}{c} \text{OMe} \\ \\ \text{OMe} \\ \end{array}$$

#### ●4 Na

- 1 REFERENCES IN FILE CA (1907 TO DATE)
- 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)
- L2 ANSWER 8 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
- RN 519060-35-6 REGISTRY
- CN Phosphoric acid, 2-cyanoethyl 2-methoxy-5-[(1Z)-2-(3,4,5-

trimethoxyphenyl)ethenyl]phenyl methyl ester (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C22 H26 N O8 P

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

DT.CA CAplus document type: Patent

RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)

Double bond geometry as shown.

# \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 9 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN

RN 519060-19-6 REGISTRY

CN 1,2-Benzenediol, 4-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, bis(dihydrogen phosphate), tetrasodium salt (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C17 H20 O11 P2 . 4 Na

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

DT.CA CAplus document type: Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Double bond geometry as shown.

$$H_2O_3PO$$
 OMe OMe OMe

# •4 Na

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 10 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN

RN 519060-15-2 REGISTRY

CN Phenol, 2,6-dimethoxy-3-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, dihydrogen phosphate, disodium salt (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C19 H23 O9 P . 2 Na

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

DT.CA CAplus document type: Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Double bond geometry as shown.

# ●2 Na

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 11 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN

RN 519060-10-7 REGISTRY

CN Phenol, 2-bromo-6-methoxy-3-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, dihydrogen phosphate, disodium salt (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C18 H20 Br O8 P . 2 Na

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

DT.CA CAplus document type: Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Double bond geometry as shown.

### ●2 Na

- 1 REFERENCES IN FILE CA (1907 TO DATE)
- 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)
- L2 ANSWER 12 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
- RN 519060-07-2 REGISTRY
- CN Phosphoric acid, mono[2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl]phenyl] monomethyl ester, ammonium salt (9CI) (CA INDEX NAME)
- FS STEREOSEARCH

MF C19 H23 O8 P . H3 N

SR CA

LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL

DT.CA CAplus document type: Journal; Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation)

Double bond geometry as shown.

# NH3

2 REFERENCES IN FILE CA (1907 TO DATE)

2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 13 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN

RN 519060-01-6 REGISTRY

CN 1,2-Benzenediol, 3-methoxy-6-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, 2,2'-(hydrogen phosphate), monosodium salt (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C36 H39 O14 P . Na

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

OT.CA CAplus document type: Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

#### 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 14 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN

RN519060-00-5 REGISTRY

CNPhenol, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, hydrogen phosphate, sodium salt (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C36 H39 O12 P . Na

SR

CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL LC STN Files:

CAplus document type: Journal; Patent DT.CA

Roles from patents: BIOL (Biological study); PREP (Preparation); USES RL.P (Uses)

Roles from non-patents: BIOL (Biological study); PREP (Preparation) RL.NP

Double bond geometry as shown.

Na

- 2 REFERENCES IN FILE CA (1907 TO DATE)
- 2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

ANSWER 15 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN L2

RN519059-99-5 REGISTRY

CN Phosphoric acid, mono[2-methoxy-5-[(1Z)-2-(3,4,5trimethoxyphenyl)ethenyl]phenyl] monooctyl ester, ammonium salt (9CI) (CA INDEX NAME)

FS STEREOSEARCH

ΜF C26 H37 O8 P . H3 N

SR

TN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL CAplus document type: Journal; Patent LC STN Files:

DT.CA

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Roles from non-patents: BIOL (Biological study); PREP (Preparation) RL.NP

# ● NH3

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 16 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN

RN 519059-97-3 REGISTRY

CN 1,3-Benzenediol, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, bis(dihydrogen phosphate), tetrasodium salt (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C18 H22 O12 P2 . 4 Na

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

DT.CA CAplus document type: Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Double bond geometry as shown.

$$H_2O_3PO$$
 OMe OMe OMe OPO $_3H_2$  OMe

#### 4 Na

- 1 REFERENCES IN FILE CA (1907 TO DATE)
- 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)
- L2 ANSWER 17 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
- RN 404886-35-7 REGISTRY
- CN Glycine, ethyl ester, compd. with 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl dihydrogen phosphate (1:1) (9CI) (CA INDEX NAME)
- FS STEREOSEARCH
- MF C18 H21 O8 P . C4 H9 N O2
- SR CA
- LC STN Files: CA, CAPLUS, USPAT2, USPATFULL
- DT.CA CAplus document type: Patent
- RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)

299

CM 1

CRN 222030-63-9 CMF C18 H21 O8 P

Double bond geometry as shown.

$$\begin{array}{c|c} & \text{OMe} \\ \hline \\ \text{OPO}_3\text{H}_2 & \text{OMe} \\ \end{array}$$

CM 2

CRN 459-73-4 CMF C4 H9 N O2

$$\begin{array}{c}
0\\ \parallel\\ \text{EtO} \neg \text{C-CH}_2 \neg \text{NH}_2
\end{array}$$

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 18 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN

RN 404886-34-6 REGISTRY

CN Glycine, methyl ester, compd. with 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl dihydrogen phosphate (1:1) (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C18 H21 O8 P . C3 H7 N O2

SR CA

LC STN Files: CA, CAPLUS, USPAT2, USPATFULL

DT.CA CAplus document type: Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)

CM 1

CRN 222030-63-9 CMF C18 H21 O8 P

$$\begin{array}{c|c} & & & \\ \hline & \\ \hline & & \\ \hline & \\ \hline & \\ \hline & & \\ \hline & \\ \hline & & \\ \hline & \\ \hline & \\ \hline & & \\ \hline & \\ \hline & & \\ \hline &$$

CRN 616-34-2 CMF C3 H7 N O2

$$\begin{array}{c} \text{O} \\ \parallel \\ \text{MeO-C-CH}_2\text{--NH}_2 \end{array}$$

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 19 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN

RN 404886-33-5 REGISTRY

CN L-Histidine, compd. with 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl dihydrogen phosphate (1:1) (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C18 H21 O8 P . C6 H9 N3 O2

SR CA

LC STN Files: CA, CAPLUS, USPAT2, USPATFULL

DT.CA CAplus document type: Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)

CM 1

CRN 222030-63-9 CMF C18 H21 O8 P

Double bond geometry as shown.

CM 2

CRN 71-00-1 CMF C6 H9 N3 O2

Absolute stereochemistry. Rotation (-).

- 1 REFERENCES IN FILE CA (1907 TO DATE)
- 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)
- L2 ANSWER 20 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN RN 404886-32-4 REGISTRY

```
299
```

1,3-Propanediol, 2-amino-2-(hydroxymethyl)-, compd. with CN2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl dihydrogen phosphate (1:1) (9CI) (CA INDEX NAME) FS STEREOSEARCH C18 H21 O8 P . C4 H11 N O3 MF SR CA, CAPLUS, USPATZ, USPATFULL LC STN Files: DT.CA CAplus document type: Patent Roles from patents: BIOL (Biological study); PREP (Preparation); PRP RL.P (Properties); USES (Uses) CM 1 CRN 222030-63-9

Double bond geometry as shown.

C18 H21 O8 P

2 CM

CMF

CRN 77-86-1 CMF C4 H11 N O3

$$\begin{array}{c} \text{NH}_2 \\ | \\ \text{HO-CH}_2\text{--C-CH}_2\text{--OH} \\ | \\ \text{CH}_2\text{--OH} \end{array}$$

1 REFERENCES IN FILE CA (1907 TO DATE) 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

ANSWER 21 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN L2400014-99-5 REGISTRY RNButanoic acid, 2-amino-4-[[imino(nitroamino)methyl]amino]-, methyl ester, CN(2S)-, compd. with 2-methoxy-5-[(1Z)-2-(3,4,5trimethoxyphenyl)ethenyl]phenyl dihydrogen phosphate (2:1) (9CI) INDEX NAME) FS STEREOSEARCH C18 H21 O8 P . 2 C6 H13 N5 O4 MF SR CA, CAPLUS, TOXCENTER, USPATFULL LC STN Files: DT.CA CAplus document type: Patent Roles from patents: BIOL (Biological study); PREP (Preparation); USES

CM 1

(Uses)

RL.P

CRN 400014-98-4 CMF C6 H13 N5 O4 Absolute stereochemistry.

CM 2

CRN 222030-63-9 CMF C18 H21 O8 P

Double bond geometry as shown.

$$MeO$$
  $OMe$   $OMe$   $OMe$ 

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 22 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN

RN 391671-20-8 REGISTRY

CN Phenol, 2-methoxy-5-[(1E)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, dihydrogen phosphate (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C18 H21 O8 P

CI COM

SR CA

LC STN Files: CA, CAPLUS, CASREACT, USPATFULL

DT.CA CAplus document type: Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 23 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN

RN 391671-18-4 REGISTRY

CN Phenol, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, dihydrogen phosphate, monopotassium salt (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C18 H21 O8 P . K

SR CA

LC STN Files: CA, CAPLUS, USPATFULL

DT.CA CAplus document type: Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

CRN (222030-63-9)

Double bond geometry as shown.

● K

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 24 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN

RN 391671-17-3 REGISTRY

CN Phenol, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, dihydrogen phosphate, manganese salt (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C18 H21 O8 P . Mn

SR CA

LC STN Files: CA, CAPLUS, USPATFULL

DT.CA CAplus document type: Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

CM 1

CRN 222030-63-9 CMF C18 H21 O8 P

CM 2

CRN 7439-96-5

CMF Mn

Mn

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 25 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN

RN 380892-83-1 REGISTRY

CN 3-Pyridinecarboxamide, compd. with 2,3-dimethoxy-5-[(1Z)-2-[4-methoxy-3-(phosphonooxy)phenyl]ethenyl]phenyl phosphate (2:1) (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C17 H20 O11 P2 . 2 C6 H6 N2 O

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

DT.CA CAplus document type: Journal; Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)

RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)

CM 1

CRN 380892-79-5

CMF C17 H20 O11 P2

Double bond geometry as shown.

CM 2

CRN 98-92-0 CMF C6 H6 N2 O

- 2 REFERENCES IN FILE CA (1907 TO DATE)
- 2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

```
299
```

380892-82-0 REGISTRY RN Phenol, 2,3-dimethoxy-5-[(1Z)-2-[4-methoxy-3-(phosphonooxy)phenyl]ethenyl]-CN , dihydrogen phosphate, compd. with morpholine (1:2) (9CI) (CA INDEX NAME) FS STEREOSEARCH C17 H20 O11 P2 . 2 C4 H9 N O MF SR LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL DT.CA CAplus document type: Journal; Patent Roles from patents: BIOL (Biological study); PREP (Preparation); PRP RL.P (Properties); USES (Uses) Roles from non-patents: BIOL (Biological study); PREP (Preparation); RL.NP PRP (Properties); USES (Uses) CM1 CRN 380892-79-5 C17 H20 O11 P2 CMF

Double bond geometry as shown.

PRP (Properties); USES (Uses)

CM 2

CRN 110-91-8 CMF C4 H9 N O



2 REFERENCES IN FILE CA (1907 TO DATE) 2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

ANSWER 27 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN L2380892-81-9 REGISTRY RN Cinchonan-9-ol, 6'-methoxy-, (9S)-, compd. with 2,3-dimethoxy-5-[(1Z)-2-[4-CN methoxy-3-(phosphonooxy)phenyl]ethenyl]phenyl phosphate (2:1) (salt) (9CI) (CA INDEX NAME) FS STEREOSEARCH MF C20 H24 N2 O2 . 1/2 C17 H20 O11 P2 SR CA, CAPLUS, TOXCENTER, USPATFULL LCCAplus document type: Journal; Patent DT.CA Roles from patents: BIOL (Biological study); PREP (Preparation); PRP RL.P (Properties); USES (Uses) Roles from non-patents: BIOL (Biological study); PREP (Preparation); RL.NP

CM 1

CRN 380892-79-5 C17 H20 O11 P2 CMF

Double bond geometry as shown.

CM 2

56-54-2 CRN C20 H24 N2 O2 CMF

Absolute stereochemistry. Rotation (+).

2 REFERENCES IN FILE CA (1907 TO DATE) 2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

ANSWER 28 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN L2

380892-80-8 REGISTRY RN

Cinchonan-9-ol, 6'-methoxy-,  $(8\alpha, 9R)$ -, compd. with CN2,3-dimethoxy-5-[(1Z)-2-[4-methoxy-3-(phosphonooxy)phenyl]ethenyl]phenyl phosphate (2:1) (salt) (9CI) (CA INDEX NAME) FS

STEREOSEARCH

MF C20 H24 N2 O2 . 1/2 C17 H20 O11 P2

SR CA

CA, CAPLUS, TOXCENTER, USPATFULL LC STN Files:

DT.CA CAplus document type: Journal; Patent

Roles from patents: BIOL (Biological study); PREP (Preparation); PRP RL.P (Properties); USES (Uses)

Roles from non-patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)

CM 1

CRN 380892-79-5 CMF C17 H20 O11 P2

CM 2

CRN 130-95-0 CMF C20 H24 N2 O2

Absolute stereochemistry.

2 REFERENCES IN FILE CA (1907 TO DATE)

2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 29 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN

RN 380892-79-5 REGISTRY

CN Phenol, 2,3-dimethoxy-5-[(1Z)-2-[4-methoxy-3-(phosphonooxy)phenyl]-

, dihydrogen phosphate (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C17 H20 O11 P2

CI COM

SR CA

LC

STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

DT.CA CAplus document type: Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

Double bond geometry as shown.

$$H_2O_3PO$$
 $Z$ 
 $OMe$ 
 $OPO_3H_2$ 

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

- 1 REFERENCES IN FILE CA (1907 TO DATE)
- 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

ANSWER 30 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN L2380892-78-4 REGISTRY RNPhenol, 2,3-dimethoxy-5-[(1Z)-2-[4-methoxy-3-(phosphonooxy)phenyl]ethenyl]-CN , dihydrogen phosphate, magnesium salt (1:2) (9CI) (CA INDEX NAME) STEREOSEARCH FS C17 H20 O11 P2 . 2 Mg MF SR LCSTN Files: CA, CAPLUS, TOXCENTER, USPATFULL DT.CA CAplus document type: Journal; Patent Roles from patents: BIOL (Biological study); PREP (Preparation); PRP RL.P (Properties); USES (Uses) Roles from non-patents: BIOL (Biological study); PREP (Preparation); RL.NP PRP (Properties); USES (Uses) (380892-79-5) CRN

Double bond geometry as shown.

### ●2 Mg

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

ANSWER 31 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN L2380892-77-3 REGISTRY RNPhenol, 2,3-dimethoxy-5-[(1Z)-2-[4-methoxy-3-(phosphonooxy)phenyl]ethenyl]-CN , dihydrogen phosphate, manganese(2+) salt (1:2) (9CI) (CA INDEX NAME) FS STEREOSEARCH C17 H20 O11 P2 . 2 Mn MF SR CA, CAPLUS, TOXCENTER, USPATFULL LC STN Files: CAplus document type: Journal; Patent DT.CA Roles from patents: BIOL (Biological study); PREP (Preparation); PRP RL.P (Properties); USES (Uses) Roles from non-patents: BIOL (Biological study); PREP (Preparation); RL.NP PRP (Properties); USES (Uses) CRN (380892-79-5)

```
2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)
```

ANSWER 32 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN L2380892-76-2 REGISTRY RNPhenol, 2,3-dimethoxy-5-[(1Z)-2-[4-methoxy-3-(phosphonooxy)phenyl]ethenyl]-CN, dihydrogen phosphate, zinc salt (1:2) (9CI) (CA INDEX NAME) FS STEREOSEARCH MF C17 H20 O11 P2 . 2 Zn SR CA, CAPLUS, TOXCENTER, USPATFULL LC DT.CA CAplus document type: Journal; Patent Roles from patents: BIOL (Biological study); PREP (Preparation); PRP RL.P (Properties); USES (Uses) Roles from non-patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses) (380892-79-5) CRN

Double bond geometry as shown.

#### •2 Zn

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2ANSWER 33 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN RN 380892-75-1 REGISTRY Phenol, 2,3-dimethoxy-5-[(1Z)-2-[4-methoxy-3-(phosphonooxy)phenyl]-thenyl]-CN, dihydrogen phosphate, calcium salt (1:2) (9CI) (CA INDEX NAME) FS STEREOSEARCH C17 H20 O11 P2 . 2 Ca MF SR LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL DT.CA CAplus document type: Journal; Patent RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses) Roles from non-patents: BIOL (Biological study); PREP (Preparation); RL.NP PRP (Properties); USES (Uses) CRN (380892-79-5)

#### ●2 Ca

2 REFERENCES IN FILE CA (1907 TO DATE) 2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

```
ANSWER 34 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
L2
    380892-74-0 REGISTRY
RN
     Phenol, 2,3-dimethoxy-5-[(1Z)-2-[4-methoxy-3-(phosphonooxy)phenyl]ethenyl]-
CN
      dihydrogen phosphate, dirubidium salt (9CI) (CA INDEX NAME)
     STEREOSEARCH
FS
     C17 H20 O11 P2 . 2 Rb
MF
SR
                  CA, CAPLUS, TOXCENTER, USPATFULL
LC
     STN Files:
      CAplus document type: Journal; Patent
DT.CA
       Roles from patents: BIOL (Biological study); PREP (Preparation); PRP
RL.P
       (Properties); USES (Uses)
       Roles from non-patents: BIOL (Biological study); PREP (Preparation);
RL.NP
       PRP (Properties); USES (Uses)
     (380892 - 79 - 5)
CRN
```

Double bond geometry as shown.

#### ● 2 Rb

- 2 REFERENCES IN FILE CA (1907 TO DATE)
  2 REFERENCES IN FILE CAPLUS (1907 TO DATE)
- ANSWER 35 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN L2380892-73-9 REGISTRY RNPhenol, 2,3-dimethoxy-5-[(1Z)-2-[4-methoxy-3-(phosphonooxy)phenyl]ethenyl]-CN, dihydrogen phosphate, dipotassium salt (9CI) (CA INDEX NAME) FS STEREOSEARCH MF C17 H20 O11 P2 . 2 K SR CA CA, CAPLUS, TOXCENTER, USPATFULL LC STN Files: DT.CA CAplus document type: Journal; Patent Roles from patents: BIOL (Biological study); PREP (Preparation); PRP RL.P (Properties); USES (Uses) Roles from non-patents: BIOL (Biological study); PREP (Preparation); RL.NP PRP (Properties); USES (Uses)

CRN (380892-79-5)

Double bond geometry as shown.

#### ●2 K

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

```
ANSWER 36 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
L2
     380892-72-8 REGISTRY
RN
     Phenol, 2,3-dimethoxy-5-[(1Z)-2-[4-methoxy-3-(phosphonooxy)phenyl]-
CN
       dihydrogen phosphate, dilithium salt (9CI) (CA INDEX NAME)
     STEREOSEARCH
FS
     C17 H20 O11 P2 . 2 Li
MF
SR
     CA
                  CA, CAPLUS, TOXCENTER, USPATFULL
LC
     STN Files:
      CAplus document type: Journal; Patent
DT.CA
       Roles from patents: BIOL (Biological study); PREP (Preparation); PRP
RL.P
       (Properties); USES (Uses)
       Roles from non-patents: BIOL (Biological study); PREP (Preparation);
RL.NP
       PRP (Properties); USES (Uses)
CRN
     (380892 - 79 - 5)
```

Double bond geometry as shown.

$$^{\mathrm{H_2O_3PO}}_{\mathrm{MeO}}$$
  $^{\mathrm{OMe}}_{\mathrm{OPO_3H_2}}$ 

### •2 Li

- 2 REFERENCES IN FILE CA (1907 TO DATE)
  2 REFERENCES IN FILE CAPLUS (1907 TO DATE)
- L2 ANSWER 37 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
- RN 380892-71-7 REGISTRY
- CN Phenol, 2,3-dimethoxy-5-[(1Z)-2-[4-methoxy-3-(phosphonooxy)phenyl]ethenyl]-, dihydrogen phosphate, disodium salt (9CI) (CA INDEX NAME)
- FS STEREOSEARCH
- MF C17 H20 O11 P2 . 2 Na
- SR CA
- LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
- DT.CA CAplus document type: Journal; Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)

RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)

CRN (380892-79-5)

Double bond geometry as shown.

#### •2 Na

2 REFERENCES IN FILE CA (1907 TO DATE)

2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 38 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN

RN 380892-70-6 REGISTRY

CN Phosphoric acid, (1Z)-1,2-ethenediylbis(6-methoxy-3,1-phenylene) tetrakis(phenylmethyl) ester (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C45 H44 O11 P2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

DT.CA CAplus document type: Journal; Patent

RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)

RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

Double bond geometry as shown.

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

- 2 REFERENCES IN FILE CA (1907 TO DATE)
- 2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

ANSWER 39 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN L2 313693-43-5 REGISTRY RN 1,2-Benzenediol, 3-methoxy-6-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, CN bis(dihydrogen phosphate), compd. with 1-[(3,4-dimethoxyphenyl)methyl]-6,7dimethoxyisoquinoline (1:4) (9CI) (CA INDEX NAME) OTHER CA INDEX NAMES: Isoquinoline, 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-, compd. with 3-methoxy-6-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-1,2-phenylene bis(dihydrogen phosphate) (4:1) (9CI) FS STEREOSEARCH C20 H21 N O4 . 1/4 C18 H22 O12 P2 MF SR CA CA, CAPLUS, IMSRESEARCH, TOXCENTER, USPATFULL LC STN Files: DT.CA CAplus document type: Journal; Patent Roles from patents: BIOL (Biological study); PREP (Preparation); USES RL.P Roles from non-patents: BIOL (Biological study); PREP (Preparation); RL.NP USES (Uses) CM1

CRN 288847-35-8 CMF C18 H22 O12 P2

Double bond geometry as shown.

$$H_2O_3PO$$
 $OPO_3H_2$ 
 $OMe$ 
 $OMe$ 
 $OMe$ 

CM 2

CRN 58-74-2 CMF C20 H21 N O4

- 2 REFERENCES IN FILE CA (1907 TO DATE)
- 2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

```
ANSWER 40 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
L2
     313693-42-4 REGISTRY
RN
     Benzeneacetonitrile, \alpha-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino
CN
     [propyl]-3,4-dimethoxy-\alpha-(1-methylethyl)-, compd. with
     3-methoxy-6-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-1,2-phenylene
     bis(dihydrogen phosphate) (4:1) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
     1,2-Benzenediol, 3-methoxy-6-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-,
CN
     bis(dihydrogen phosphate), compd. with \alpha-[3-[[2-(3,4-
     dimethoxyphenyl) ethyl] methylamino] propyl] -3, 4 - dimethoxy-\alpha-(1-
     methylethyl)benzeneacetonitrile (1:4) (9CI)
     STEREOSEARCH
FS
     C27 H38 N2 O4 . 1/4 C18 H22 O12 P2
MF
SR
                  CA, CAPLUS, IMSRESEARCH, TOXCENTER, USPATFULL
LC
       CAplus document type: Journal; Patent
DT.CA
       Roles from patents: BIOL (Biological study); PREP (Preparation); USES
RL.P
       (Uses)
       Roles from non-patents: BIOL (Biological study); PREP (Preparation);
RL.NP
       USES (Uses)
     CM
          1
          288847-35-8
     CRN
```

Double bond geometry as shown.

C18 H22 O12 P2

$$H_2O_3PO$$
 $E$ 
 $OPO_3H_2$ 
 $E$ 
 $OMe$ 
 $OMe$ 
 $OMe$ 

CM 2

 $\mathsf{CMF}$ 

CRN 52-53-9 CMF C27 H38 N2 O4

MeO Pr-i Me OMe OMe 
$$CH_2 - CH_2 - CH_2$$

- 2 REFERENCES IN FILE CA (1907 TO DATE)
  2 REFERENCES IN FILE CAPLUS (1907 TO DATE)
- L2 ANSWER 41 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN RN 313692-49-8 REGISTRY
- CN Cinchonan-9-ol, 6'-methoxy-, (9S)-, compd. with 3-methoxy-6-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-1,2-phenylene bis(dihydrogen phosphate) (4:1)

(9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 1,2-Benzenediol, 3-methoxy-6-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, bis(dihydrogen phosphate), compd. with (9S)-6'-methoxycinchonan-9-ol (1:4) (9CI)

FS STEREOSEARCH

MF C20 H24 N2 O2 . 1/4 C18 H22 O12 P2

SR CA

LC STN Files: CA, CAPLUS, IMSRESEARCH, TOXCENTER, USPATFULL

DT.CA CAplus document type: Journal; Patent

CM 1

CRN 288847-35-8 CMF C18 H22 O12 P2

Double bond geometry as shown.

CM 2

CRN 56-54-2 CMF C20 H24 N2 O2

Absolute stereochemistry. Rotation (+).

- 2 REFERENCES IN FILE CA (1907 TO DATE)
- 2 REFERENCES IN FILE CAPLUS (1907 TO DATE)
- L2 ANSWER 42 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
- RN 313692-48-7 REGISTRY
- CN Cinchonan-9-ol, 6'-methoxy-,  $(8\alpha, 9R)$ -, compd. with 3-methoxy-6-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-1,2-phenylene bis(dihydrogen phosphate) (4:1) (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

1,2-Benzenediol, 3-methoxy-6-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, bis(dihydrogen phosphate), compd. with (8α,9R)-6'-methoxycinchonan-9-ol (1:4) (9CI)

FS STEREOSEARCH

MF C20 H24 N2 O2 . 1/4 C18 H22 O12 P2

SR CA

LC STN Files: CA, CAPLUS, IMSRESEARCH, TOXCENTER, USPATFULL

DT.CA CAplus document type: Journal; Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

CM 1

CRN 288847-35-8 CMF C18 H22 O12 P2

Double bond geometry as shown.

CM 2

CRN 130-95-0 CMF C20 H24 N2 O2

Absolute stereochemistry.

- 2 REFERENCES IN FILE CA (1907 TO DATE)
- 2 REFERENCES IN FILE CAPLUS (1907 TO DATE)
- L2 ANSWER 43 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
- RN 313692-47-6 REGISTRY
- CN 1,2-Benzenediol, 3-methoxy-6-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, bis(dihydrogen phosphate), compd. with morpholine (1:4) (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

```
Morpholine, compd. with 3-methoxy-6-[(1Z)-2-(3,4,5-
CN
    trimethoxyphenyl)ethenyl]-1,2-phenylene bis(dihydrogen phosphate) (4:1)
    STEREOSEARCH
FS
    C18 H22 O12 P2 . 4 C4 H9 N O
MF
SR
                  CA, CAPLUS, IMSRESEARCH, TOXCENTER, USPATFULL
LC
     STN Files:
      CAplus document type: Journal; Patent
DT.CA
       Roles from patents: BIOL (Biological study); PREP (Preparation); USES
RL.P
      Roles from non-patents: BIOL (Biological study); PREP (Preparation);
RL.NP
       USES (Uses)
     CM
          1
```

CRN 288847-35-8 CMF C18 H22 O12 P2

Double bond geometry as shown.

CM 2

CRN 110-91-8 CMF C4 H9 N O

313692-46-5 REGISTRY



L2

RN

```
2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)
```

ANSWER 44 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN

```
1,2-Benzenediol, 3-methoxy-6-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-,
CN
    bis(dihydrogen phosphate), zinc salt (1:2) (9CI) (CA INDEX NAME)
    STEREOSEARCH
FS
    C18 H22 O12 P2 . 2 Zn
MF
SR
    CA
                  CA, CAPLUS, IMSRESEARCH, TOXCENTER, USPATFULL
     STN Files:
LC
      CAplus document type: Journal; Patent
DT.CA
      Roles from patents: BIOL (Biological study); PREP (Preparation); USES
RL.P
       (Uses)
      Roles from non-patents: BIOL (Biological study); PREP (Preparation);
RL.NP
       USES (Uses)
     (288847-35-8)
CRN
```

Double bond geometry as shown.

$$\begin{array}{c} \text{OPO}_3\text{H}_2\\ \text{H}_2\text{O}_3\text{PO} \\ \text{MeO} \end{array} \begin{array}{c} \text{OMe} \\ \text{OMe} \\ \end{array}$$

#### Zn

2 REFERENCES IN FILE CA (1907 TO DATE) 2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

ANSWER 45 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN L2313692-45-4 REGISTRY RN1,2-Benzenediol, 3-methoxy-6-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, CNbis(dihydrogen phosphate), manganese(2+) salt (1:2) (9CI) (CA INDEX NAME) STEREOSEARCH FS MF C18 H22 O12 P2 . 2 Mn SR CACA, CAPLUS, IMSRESEARCH, TOXCENTER, USPATFULL LC CAplus document type: Journal; Patent DT.CA Roles from patents: BIOL (Biological study); PREP (Preparation); USES RL.P (Uses) Roles from non-patents: BIOL (Biological study); PREP (Preparation); RL.NP USES (Uses) (288847 - 35 - 8)CRN

Double bond geometry as shown.

### 2 Mn(II)

MF

- 2 REFERENCES IN FILE CA (1907 TO DATE) 2 REFERENCES IN FILE CAPLUS (1907 TO DATE)
- ANSWER 46 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN L2313692-44-3 REGISTRY RN1,2-Benzenediol, 3-methoxy-6-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, CN bis(dihydrogen phosphate), calcium salt (1:2) (9CI) (CA INDEX NAME) FS STEREOSEARCH C18 H22 O12 P2 . 2 Ca

LC

SR CA

STN Files: CA, CAPLUS, IMSRESEARCH, TOXCENTER, USPATFULL

OT.CA CAplus document type: Journal; Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

CRN (288847-35-8)

Double bond geometry as shown.

#### ●2 Ca

2 REFERENCES IN FILE CA (1907 TO DATE)

2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 47 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN

RN 313692-43-2 REGISTRY

CN 1,2-Benzenediol, 3-methoxy-6-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, bis(dihydrogen phosphate), magnesium salt (1:2) (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C18 H22 O12 P2 . 2 Mg

SR CA

LC STN Files: CA, CAPLUS, IMSRESEARCH, TOXCENTER, USPATFULL

DT.CA CAplus document type: Journal; Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

CRN (288847-35-8)

Double bond geometry as shown.

$$H_2O_3PO$$
 $OPO_3H_2$ 
 $OMe$ 
 $OMe$ 
 $OMe$ 

# ●2 Mg

CRN

# 2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

ANSWER 48 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN L2313692-42-1 REGISTRY RN 1,2-Benzenediol, 3-methoxy-6-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, CN bis(dihydrogen phosphate), tetracesium salt (9CI) (CA INDEX NAME) FS STEREOSEARCH C18 H22 O12 P2 . 4 Cs MF SR CA STN Files: CA, CAPLUS, IMSRESEARCH, TOXCENTER, USPATFULL LCDT.CA CAplus document type: Journal; Patent Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses) RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Double bond geometry as shown.

(288847 - 35 - 8)

$$H_2O_3PO$$
  $OPO_3H_2$   $OMe$   $OMe$   $OMe$ 

# •4 Cs

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

ANSWER 49 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN L2RN 313692-41-0 REGISTRY CN1,2-Benzenediol, 3-methoxy-6-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, bis(dihydrogen phosphate), tetrapotassium salt (9CI) (CA INDEX NAME) FS STEREOSEARCH MF C18 H22 O12 P2 . 4 K SR CA CA, CAPLUS, IMSRESEARCH, TOXCENTER, USPATFULL LCSTN Files: CAplus document type: Journal; Patent DT.CA Roles from patents: BIOL (Biological study); PREP (Preparation); USES RL.P (Uses) RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Double bond geometry as shown.

(288847-35-8)

CRN

$$H_2O_3PO$$
 $OPO_3H_2$ 
 $OMe$ 
 $OMe$ 
 $OMe$ 

#### ●4 K

- 2 REFERENCES IN FILE CA (1907 TO DATE)
- 2 REFERENCES IN FILE CAPLUS (1907 TO DATE)
- L2 ANSWER 50 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN

RN 313692-39-6 REGISTRY

CN 1,2-Benzenediol, 3-methoxy-6-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, bis(dihydrogen phosphate), tetralithium salt (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C18 H22 O12 P2 . 4 Li

SR CA

LC STN Files: CA, CAPLUS, CASREACT, IMSRESEARCH, TOXCENTER, USPATFULL

DT.CA CAplus document type: Journal; Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

CRN (288847-35-8)

Double bond geometry as shown.

$$H_2O_3PO$$
 $OPO_3H_2$ 
 $OMe$ 
 $OMe$ 
 $OMe$ 

### ●4 Li

- 2 REFERENCES IN FILE CA (1907 TO DATE)
- 2 REFERENCES IN FILE CAPLUS (1907 TO DATE)
- L2 ANSWER 51 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
- RN 313692-37-4 REGISTRY
- CN Phosphoric acid, 3-methoxy-6-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-1,2-phenylene tetraethyl ester (9CI) (CA INDEX NAME)
  OTHER NAMES:
- CN 2',3'-O-Di[bisethylphosphoryl]combretastatin A1
- FS STEREOSEARCH
- MF C26 H38 O12 P2
- SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

DT.CA CAplus document type: Journal; Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

RL.NP Roles from non-patents: PREP (Preparation)

Double bond geometry as shown.

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

2 REFERENCES IN FILE CA (1907 TO DATE)

2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 52 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN

RN 313692-35-2 REGISTRY

CN Phosphoric acid, 3-methoxy-6-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-1,2-phenylene tetrakis(phenylmethyl) ester (9CI) (CA INDEX NAME)

OTHER NAMES:

CN (Z)-2-(2,3-Bis((bis(benzyloxy)phosphinyl)oxy)-4-methoxyphenyl)-1-(3,4,5-trimethoxyphenyl)ethene

CN 2',3'-O-Di[bisbenzylphosphoryl]combretastatin A1

FS STEREOSEARCH

MF C46 H46 O12 P2

SR CA

LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL

DT.CA CAplus document type: Journal; Patent

RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)

RL.NP Roles from non-patents: PREP (Preparation); RACT (Reactant or reagent)

# \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

- 2 REFERENCES IN FILE CA (1907 TO DATE) 2 REFERENCES IN FILE CAPLUS (1907 TO DATE)
- L2 ANSWER 53 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN

RN 288847-37-0 REGISTRY

3-Pyridinecarboxamide, compd. with 3-methoxy-6-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-1,2-phenylene bis(dihydrogen phosphate) (4:1) (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 1,2-Benzenediol, 3-methoxy-6-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, bis(dihydrogen phosphate), compd. with 3-pyridinecarboxamide (1:4) (9CI)

FS STEREOSEARCH

MF C18 H22 O12 P2 . 4 C6 H6 N2 O

SR CA

LC STN Files: CA, CAPLUS, IMSRESEARCH, TOXCENTER, USPATFULL

DT.CA CAplus document type: Journal; Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)

RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

CM 1

CRN 288847-35-8 CMF C18 H22 O12 P2

Double bond geometry as shown.

CM 2

CRN 98-92-0 CMF C6 H6 N2 O

- 3 REFERENCES IN FILE CA (1907 TO DATE)
- 3 REFERENCES IN FILE CAPLUS (1907 TO DATE)
- L2 ANSWER 54 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN 288847-36-9 REGISTRY

CN 1,2-Benzenediol, 3-methoxy-6-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, bis(dihydrogen phosphate), compd. with piperazine (1:2) (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Piperazine, compd. with 3-methoxy-6-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-1,2-phenylene bis(dihydrogen phosphate) (2:1) (9CI)

FS STEREOSEARCH

MF C18 H22 O12 P2 . 2 C4 H10 N2

SR CA

LC STN Files: CA, CAPLUS, IMSRESEARCH, TOXCENTER, USPATFULL

DT.CA CAplus document type: Journal; Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)

RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

CM 1

CRN 288847-35-8 CMF C18 H22 O12 P2

Double bond geometry as shown.

CM 2

CRN 110-85-0 CMF C4 H10 N2



- 3 REFERENCES IN FILE CA (1907 TO DATE)
- 3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 55 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN

RN 288847-35-8 REGISTRY

CN 1,2-Benzenediol, 3-methoxy-6-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, bis(dihydrogen phosphate) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN Oxi 4503

FS STEREOSEARCH

MF C18 H22 O12 P2

CI COM

SR CA

LC STN Files: CA, CAPLUS, IMSRESEARCH, PROUSDDR, SYNTHLINE, TOXCENTER

DT.CA CAplus document type: Journal

RL.NP Roles from non-patents: BIOL (Biological study); USES (Uses)

Double bond geometry as shown.

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

2 REFERENCES IN FILE CA (1907 TO DATE)

2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 56 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN

RN 288847-34-7 REGISTRY

CN 1,2-Benzenediol, 3-methoxy-6-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, bis(dihydrogen phosphate), tetrasodium salt (9CI) (CA INDEX NAME)
OTHER NAMES:

CN Combretastatin A-1 phosphate

FS STEREOSEARCH

MF C18 H22 O12 P2 . 4 Na

SR CA

LC STN Files: BIOSIS, CA, CAPLUS, CASREACT, EMBASE, IMSRESEARCH, PROUSDDR, SYNTHLINE, TOXCENTER, USPATFULL

DT.CA CAplus document type: Journal; Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); USES (Uses)

RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

CRN (288847-35-8)

$$\begin{array}{c} \text{OPO}_3\text{H}_2\\ \text{H}_2\text{O}_3\text{PO} \\ \text{MeO} \end{array} \begin{array}{c} \text{OMe} \\ \text{OMe} \\ \end{array}$$

# 8 REFERENCES IN FILE CAPLUS (1907 TO DATE)

ANSWER 57 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN L2 229178-48-7 REGISTRY RNBenzeneacetonitrile,  $\alpha$ -[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino CN  $[propyl]-3,4-dimethoxy-\alpha-(1-methylethyl)-, compd. with$ 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl dihydrogen phosphate (1:1) (9CI) (CA INDEX NAME) OTHER CA INDEX NAMES: Phenol, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, dihydrogen phosphate, compd. with  $\alpha$ -[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylami no]propyl]-3,4-dimethoxy- $\alpha$ -(1-methylethyl)benzeneacetonitrile (1:1) (9CI) STEREOSEARCH FS C27 H38 N2 O4 . C18 H21 O8 P MF SR

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL DT.CA CAplus document type: Journal; Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)

CM 1

CRN 222030-63-9 CMF C18 H21 O8 P

Double bond geometry as shown.

CM 2

CRN 52-53-9 CMF C27 H38 N2 O4

MeO 
$$Pr-i$$
 Me  $OMe$   $OM$ 

- 3 REFERENCES IN FILE CA (1907 TO DATE)
- 3 REFERENCES IN FILE CAPLUS (1907 TO DATE)
- L2 ANSWER 58 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
- RN 229178-47-6 REGISTRY
- CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aS,5aS,6S,12aS)-,

compd. with 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl dihydrogen phosphate (1:1) (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

Phenol, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, dihydrogen phosphate, compd. with (4S,4aS,5aS,6S,12aS)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide (1:1) (9CI)

FS STEREOSEARCH

MF C22 H24 N2 O8 . C18 H21 O8 P

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

DT.CA CAplus document type: Journal; Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)

CM 1

CRN 222030-63-9 CMF C18 H21 O8 P

Double bond geometry as shown.

CM 2

CRN 60-54-8 CMF C22 H24 N2 O8

Absolute stereochemistry. Rotation (-).

- 3 REFERENCES IN FILE CA (1907 TO DATE)
- 3 REFERENCES IN FILE CAPLUS (1907 TO DATE)
- L2 ANSWER 59 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN

RN 229178-46-5 REGISTRY

CN Cinchonan-9-ol, 6'-methoxy-, (9S)-, compd. with 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl dihydrogen phosphate (1:1) (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Phenol, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, dihydrogen

phosphate, compd. with (9S)-6'-methoxycinchonan-9-ol (1:1) (9CI) STEREOSEARCH FS C20 H24 N2 O2 . C18 H21 O8 P MF SR CA, CAPLUS, TOXCENTER, USPATFULL STN Files: LC CAplus document type: Journal; Patent DT.CA Roles from patents: BIOL (Biological study); PREP (Preparation); USES RL.P (Uses) Roles from non-patents: BIOL (Biological study); PREP (Preparation); RL.NP PRP (Properties); USES (Uses) CM 1

CRN 222030-63-9 CMF C18 H21 O8 P

Double bond geometry as shown.

CM 2

CRN 56-54-2 CMF C20 H24 N2 O2

Absolute stereochemistry. Rotation (+).

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

(CA INDEX NAME)

- L2 ANSWER 60 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
- RN 229178-45-4 REGISTRY
- CN Cinchonan-9-ol, 6'-methoxy-,  $(8\alpha, 9R)$ -, compd. with 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl dihydrogen

phosphate (1:1) (9CI) OTHER CA INDEX NAMES:

- CN Phenol, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, dihydrogen phosphate, compd. with (8α,9R)-6'-methoxycinchonan-9-ol (1:1) (9CI)
- FS STEREOSEARCH
- MF C20 H24 N2 O2 . C18 H21 O8 P
- SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

DT.CA CAplus document type: Journal; Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)

CM 1

CRN 222030-63-9 CMF C18 H21 O8 P

Double bond geometry as shown.

$$\begin{array}{c|c} & & \text{OMe} \\ \hline & & \\ & & \text{OPO}_3\text{H}_2 & \text{OMe} \\ \end{array}$$

CM 2

CRN 130-95-0 CMF C20 H24 N2 O2

Absolute stereochemistry.

- 3 REFERENCES IN FILE CA (1907 TO DATE)
- 3 REFERENCES IN FILE CAPLUS (1907 TO DATE)
- L2 ANSWER 61 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
- RN 229178-43-2 REGISTRY
- CN D-Glucose, 2-amino-2-deoxy-, compd. with 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl dihydrogen phosphate (1:1) (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Phenol, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, dihydrogen phosphate, compd. with 2-amino-2-deoxy-D-glucose (1:1) (9CI)

FS STEREOSEARCH

MF C18 H21 O8 P . C6 H13 N O5

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

DT.CA CAplus document type: Journal; Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)

CM 1

CRN 222030-63-9 CMF C18 H21 O8 P

Double bond geometry as shown.

$$MeO$$
  $OMe$   $OMe$   $OMe$   $OMe$ 

CM 2

CRN 3416-24-8 CMF C6 H13 N O5

Absolute stereochemistry. Rotation (+).

3 REFERENCES IN FILE CA (1907 TO DATE)

3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 62 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN

RN 229178-42-1 REGISTRY

CN Cinchonan-9-ol, (9S)-, compd. with 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl dihydrogen phosphate (1:1) (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Phenol, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, dihydrogen phosphate, compd. with (9S)-cinchonan-9-ol (1:1) (9CI)

FS STEREOSEARCH

MF C19 H22 N2 O . C18 H21 O8 P

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

DT.CA CAplus document type: Journal; Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)

CM 1

CRN 222030-63-9 CMF C18 H21 O8 P

CRN 118-10-5 CMF C19 H22 N2 O

Absolute stereochemistry. Rotation (+).

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 63 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN

RN 229178-41-0 REGISTRY

CN Adenosine, compd. with 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl dihydrogen phosphate (1:1) (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Phenol, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, dihydrogen phosphate, compd. with adenosine (1:1) (9CI)

FS STEREOSEARCH

MF C18 H21 O8 P . C10 H13 N5 O4

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

DT.CA CAplus document type: Journal; Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

CM 1

CRN 222030-63-9 CMF C18 H21 O8 P

CRN 58-61-7 CMF C10 H13 N5 O4

Absolute stereochemistry.

- 3 REFERENCES IN FILE CA (1907 TO DATE)
- 3 REFERENCES IN FILE CAPLUS (1907 TO DATE)
- L2 ANSWER 64 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN

RN 229178-40-9 REGISTRY

CN Phenol, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, dihydrogen phosphate, compd. with pyridine (1:1) (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C18 H21 O8 P . C5 H5 N

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

DT.CA CAplus document type: Journal; Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)

CM 1

CRN 222030-63-9 CMF C18 H21 O8 P

CRN 110-86-1 CMF C5 H5 N



3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 65 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN

RN 229178-39-6 REGISTRY

CN Phenol, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, dihydrogen phosphate, compd. with 1H-pyrazole (1:1) (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 1H-Pyrazole, compd. with 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl dihydrogen phosphate (1:1) (9CI)

FS STEREOSEARCH

MF C18 H21 O8 P . C3 H4 N2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

DT.CA CAplus document type: Journal; Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)

CM 1

CRN 222030-63-9 CMF C18 H21 O8 P

Double bond geometry as shown.

$$MeO$$
  $OPO_3H_2$   $OMe$   $OMe$ 

CM 2

CRN 288-13-1 CMF C3 H4 N2



3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 66 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN

RN 229178-38-5 REGISTRY

CN Phenol, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, dihydrogen phosphate, compd. with piperidine (1:1) (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Piperidine, compd. with 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl dihydrogen phosphate (1:1) (9CI)

FS STEREOSEARCH

MF C18 H21 O8 P . C5 H11 N

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

DT.CA CAplus document type: Journal; Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)

CM 1

CRN 222030-63-9 CMF C18 H21 O8 P

Double bond geometry as shown.

CM 2

CRN 110-89-4 CMF C5 H11 N



- 3 REFERENCES IN FILE CA (1907 TO DATE)
- 3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 67 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN

RN 229178-37-4 REGISTRY

CN Phenol, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, dihydrogen phosphate, compd. with piperazine (1:1) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:

CN Piperazine, compd. with 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl dihydrogen phosphate (1:1) (9CI)

FS STEREOSEARCH

MF C18 H21 O8 P . C4 H10 N2

SR CA

CA, CAPLUS, TOXCENTER, USPATFULL STN Files: LCDT.CA CAplus document type: Journal; Patent Roles from patents: BIOL (Biological study); PREP (Preparation); USES RL.P (Uses) Roles from non-patents: BIOL (Biological study); PREP (Preparation); RL.NP PRP (Properties); USES (Uses) CM 1

222030-63-9 CRN C18 H21 O8 P CMF

Double bond geometry as shown.

$$\begin{array}{c|c} & & & \text{OMe} \\ \hline & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & &$$

CM 2

CRN 110-85-0 CMF C4 H10 N2



- 3 REFERENCES IN FILE CA (1907 TO DATE) 3 REFERENCES IN FILE CAPLUS (1907 TO DATE)
- ANSWER 68 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN L2

229178-36-3 REGISTRY RN

Phenol, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, dihydrogen CNphosphate, compd. with morpholine (1:1) (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

Morpholine, compd. with 2-methoxy-5-[(1Z)-2-(3,4,5-CN

trimethoxyphenyl)ethenyl]phenyl dihydrogen phosphate (1:1) (9CI)

FS STEREOSEARCH

MF C18 H21 O8 P . C4 H9 N O

SR

CA, CAPLUS, TOXCENTER, USPATFULL STN Files:

LC CAplus document type: Journal; Patent DT.CA

Roles from patents: BIOL (Biological study); PREP (Preparation); USES RL.P

Roles from non-patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)

CM 1

CRN 222030-63-9 CMF C18 H21 O8 P Double bond geometry as shown.

CM 2

CRN 110-91-8 CMF C4 H9 N O



3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

ANSWER 69 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN L2229178-35-2 REGISTRY RNPhenol, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, dihydrogen CNphosphate, compd. with 1H-imidazole (1:1) (9CI) (CA INDEX NAME) OTHER CA INDEX NAMES: 1H-Imidazole, compd. with 2-methoxy-5-[(1Z)-2-(3,4,5-CNtrimethoxyphenyl)ethenyl]phenyl dihydrogen phosphate (1:1) (9CI) FS STEREOSEARCH C18 H21 O8 P . C3 H4 N2 MF SR CA, CAPLUS, TOXCENTER, USPATFULL STN Files: LC CAplus document type: Journal; Patent DT.CA Roles from patents: BIOL (Biological study); PREP (Preparation); USES RL.P (Uses) Roles from non-patents: BIOL (Biological study); PREP (Preparation); RL.NP PRP (Properties); USES (Uses)

CM 1

CRN 222030-63-9 CMF C18 H21 O8 P

$${\sf MeO}$$
  ${\sf OMe}$   ${\sf OMe}$   ${\sf OMe}$   ${\sf OMe}$ 

CRN 288-32-4 CMF C3 H4 N2



3 REFERENCES IN FILE CA (1907 TO DATE)

3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 70 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN

RN 229178-31-8 REGISTRY

CN Phenol, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, dihydrogen phosphate, monolithium salt (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C18 H21 O8 P . Li

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

DT.CA CAplus document type: Journal; Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)

CRN (222030-63-9)

Double bond geometry as shown.

$$\begin{array}{c|c} & & & \text{OMe} \\ \hline & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & &$$

### Li

- 3 REFERENCES IN FILE CA (1907 TO DATE)
- 3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 71 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN

RN 229178-30-7 REGISTRY

CN Phenol, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, dihydrogen phosphate, monocesium salt (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C18 H21 O8 P . Cs

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

DT.CA CAplus document type: Journal; Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)

299

CRN (222030-63-9)

Double bond geometry as shown.

● Cs

- 3 REFERENCES IN FILE CA (1907 TO DATE)
- 3 REFERENCES IN FILE CAPLUS (1907 TO DATE)
- L2 ANSWER 72 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN

RN 229178-29-4 REGISTRY

CN Phenol, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, dihydrogen phosphate, calcium salt (1:1) (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C18 H21 O8 P . Ca

SR CA

- LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
- DT.CA CAplus document type: Journal; Patent
- RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
- RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)

CRN (222030-63-9)

Double bond geometry as shown.

$$\begin{array}{c|c} & \text{OMe} \\ \hline & \text{OPO}_3\text{H}_2 & \text{OMe} \\ \end{array}$$

## • Ca

- 3 REFERENCES IN FILE CA (1907 TO DATE)
- 3 REFERENCES IN FILE CAPLUS (1907 TO DATE)
- L2 ANSWER 73 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
- RN 229178-28-3 REGISTRY
- CN Phenol, 2-methoxy-5-[(1E)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, dihydrogen
  phosphate, disodium salt (9CI) (CA INDEX NAME)
- FS STEREOSEARCH
- MF C18 H21 O8 P . 2 Na
- SR CA
- LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
- DT.CA CAplus document type: Journal; Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

RL.NP Roles from non-patents: BIOL (Biological study); USES (Uses) CRN (391671-20-8)

Double bond geometry as shown.

#### ●2 Na

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 74 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN

RN 229178-27-2 REGISTRY

CN Phosphoric acid, 2-methoxy-5-[(1E)-2-(3,4,5-trimethoxyphenyl)ethenyl]pheny l bis(phenylmethyl) ester (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C32 H33 O8 P

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

DT.CA CAplus document type: Journal; Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

RL.NP Roles from non-patents: PREP (Preparation); RACT (Reactant or reagent)

## \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

- 2 REFERENCES IN FILE CA (1907 TO DATE)
- 2 REFERENCES IN FILE CAPLUS (1907 TO DATE)
- L2 ANSWER 75 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN

RN 226989-84-0 REGISTRY

CN Phenol, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, dihydrogen phosphate, monosodium salt (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C18 H21 O8 P . Na

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

DT.CA CAplus document type: Journal; Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)

CRN (222030-63-9)

Double bond geometry as shown.

### ма

- 4 REFERENCES IN FILE CA (1907 TO DATE)
- 4 REFERENCES IN FILE CAPLUS (1907 TO DATE)
- L2 ANSWER 76 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
- RN 222030-63-9 REGISTRY
- CN Phenol, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, dihydrogen phosphate (9CI) (CA INDEX NAME)

OTHER NAMES:

CN Combretastatin A4 phosphate

FS STEREOSEARCH

MF C18 H21 O8 P

CI COM

SR CA

LC STN Files: BIOSIS, CA, CAPLUS, CASREACT, EMBASE, IMSRESEARCH, PROUSDDR, TOXCENTER, USPAT2, USPATFULL

DT.CA CAplus document type: Conference; Journal; Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)

RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); USES (Uses)

Double bond geometry as shown.

# \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

38 REFERENCES IN FILE CA (1907 TO DATE) 39 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 77 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN

RN 208465-89-8 REGISTRY

CN Phosphoric acid, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]pheny l bis[2-(trimethylsilyl)ethyl] ester (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C28 H45 O8 P Si2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

DT.CA CAplus document type: Journal; Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

RL.NP Roles from non-patents: PREP (Preparation); RACT (Reactant or reagent)

Double bond geometry as shown.

## \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

## 2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 78 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN

RN 208465-88-7 REGISTRY

CN Phosphoric acid, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]pheny

1 bis(phenylmethyl) ester (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C32 H33 O8 P

SR CA

LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL

DT.CA CAplus document type: Journal; Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

RL.NP Roles from non-patents: PREP (Preparation); RACT (Reactant or reagent)

Double bond geometry as shown.

# \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

- 3 REFERENCES IN FILE CA (1907 TO DATE)
  3 REFERENCES IN FILE CAPLUS (1907 TO DATE)
- L2 ANSWER 79 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN

RN 174909-45-6 REGISTRY

CN Phosphoric acid, bis(1,1-dimethylethyl) 2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl ester, (E)- (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C26 H37 O8 P

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER

DT.CA CAplus document type: Journal

RL.NP Roles from non-patents: PREP (Preparation)

## \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

- 1 REFERENCES IN FILE CA (1907 TO DATE)
- 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)
- L2 ANSWER 80 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
- RN 174909-40-1 REGISTRY
- CN Phenol, 2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)ethenyl]-, dihydrogen phosphate, diammonium salt, (Z)- (9CI) (CA INDEX NAME)
- FS STEREOSEARCH
- MF C18 H21 O8 P . 2 H3 N
- SR CA
- LC STN Files: CA, CAPLUS, TOXCENTER
- DT.CA CAplus document type: Journal
- RL.NP Roles from non-patents: PREP (Preparation); RACT (Reactant or reagent) CRN (222030-63-9)

Double bond geometry as shown.

$$\begin{array}{c|c} & & \text{OMe} \\ \hline & & \\ & & \text{OPO}_3\text{H}_2 & \text{OMe} \\ \end{array}$$

## ●2 NH<sub>3</sub>

- 1 REFERENCES IN FILE CA (1907 TO DATE)
- 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)
- L2 ANSWER 81 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
- RN 168555-66-6 REGISTRY
- CN Phenol, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, dihydrogen phosphate, disodium salt (9CI) (CA INDEX NAME)
- OTHER CA INDEX NAMES:
- CN Phenol, 2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)ethenyl]-, dihydrogen
   phosphate, disodium salt, (Z)OTHER NAMES:

```
CN
    CA 4P
    Combretastatin A4 disodium phosphate
CN
    STEREOSEARCH
FS
    229027-07-0
DR
    C18 H21 O8 P . 2 Na
MF
SR
                 BIOSIS, CA, CAPLUS, CASREACT, EMBASE, IMSDRUGNEWS,
     STN Files:
LC
       IMSRESEARCH, PROUSDDR, TOXCENTER, USPATZ, USPATFULL
       CAplus document type: Dissertation; Journal; Patent
DT.CA
       Roles from patents: BIOL (Biological study); PREP (Preparation); PROC
RL.P
       (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)
       Roles from non-patents: BIOL (Biological study); PREP (Preparation);
RL.NP
       PROC (Process); USES (Uses)
RLD.NP Roles for non-specific derivatives from non-patents: BIOL (Biological
       study); PREP (Preparation)
     (222030-63-9)
CRN
```

Double bond geometry as shown.

## ●2 Na

- 51 REFERENCES IN FILE CA (1907 TO DATE)
- 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
- 53 REFERENCES IN FILE CAPLUS (1907 TO DATE)

```
ANSWER 82 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
L2
     168555-65-5 REGISTRY
RN
     Phosphoric acid, 2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl
CN
    bis(2,2,2-trichloroethyl) ester, (Z)- (9CI) (CA INDEX NAME)
FS
     STEREOSEARCH
     C22 H23 C16 O8 P
MF
SR
                 CA, CAPLUS, TOXCENTER, USPATFULL
     STN Files:
LC
      CAplus document type: Journal; Patent
DT.CA
      Roles from patents: PREP (Preparation); RACT (Reactant or reagent)
      Roles from non-patents: PREP (Preparation); RACT (Reactant or reagent)
```

# \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

- 2 REFERENCES IN FILE CA (1907 TO DATE)
- 2 REFERENCES IN FILE CAPLUS (1907 TO DATE)
- L2 ANSWER 83 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN

RN 145545-17-1 REGISTRY

CN Phenol, 2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)ethenyl]-, dihydrogen

phosphate, dipotassium salt, (Z) - (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C18 H21 O8 P . 2 K

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

DT.CA CAplus document type: Journal; Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)

RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation) CRN (222030-63-9)

Double bond geometry as shown.

## ●2 K

- 4 REFERENCES IN FILE CA (1907 TO DATE)
- 4 REFERENCES IN FILE CAPLUS (1907 TO DATE)
- L2 ANSWER 84 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
- RN 145545-16-0 REGISTRY
- CN Phenol, 2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)ethenyl]-, dihydrogen phosphate, monoammonium salt, (Z)- (9CI) (CA INDEX NAME)
- FS STEREOSEARCH
- MF C18 H21 O8 P . H3 N
- SR CA
- LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
- DT.CA CAplus document type: Journal; Patent
- RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

RL.NP Roles from non-patents: PREP (Preparation); RACT (Reactant or reagent) CRN (222030-63-9)

Double bond geometry as shown.

## NH<sub>3</sub>

- 3 REFERENCES IN FILE CA (1907 TO DATE)
- 3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 85 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN

RN 145545-15-9 REGISTRY

CN Phosphoric acid, bis(1,1-dimethylethyl) 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl ester (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Phosphoric acid, bis(1,1-dimethylethyl) 2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl ester, (Z)-

FS STEREOSEARCH

MF C26 H37 O8 P

SR CA

LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL

DT.CA CAplus document type: Journal; Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

RL.NP Roles from non-patents: PREP (Preparation); RACT (Reactant or reagent)

Double bond geometry as shown.

$$H_3C$$
 $CH_3$ 
 $H_3C$ 
 $CH_3$ 
 $CH_3$ 
 $CH_3$ 
 $CH_3$ 
 $CH_3$ 
 $CH_3$ 

### \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

- 5 REFERENCES IN FILE CA (1907 TO DATE)
- 5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 306.29 306.50

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 15:31:47 ON 26 MAY 2004 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 26 May 2004 VOL 140 ISS 22 FILE LAST UPDATED: 25 May 2004 (20040525/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 12 L3 99 L2

=> d 1-99 bib absl3
'ABSL3' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS ----- GI and AB ALL ----- BIB, AB, IND, RE APPS ----- AI, PRAI BIB ----- AN, plus Bibliographic Data and PI table (default) CAN ----- List of CA abstract numbers without answer numbers CBIB ----- AN, plus Compressed Bibliographic Data DALL ----- ALL, delimited (end of each field identified) DMAX ----- MAX, delimited for post-processing FAM ----- AN, PI and PRAI in table, plus Patent Family data FBIB ----- AN, BIB, plus Patent FAM IND ----- Indexing data IPC ----- International Patent Classifications MAX ----- ALL, plus Patent FAM, RE PATS ----- PI, SO SAM ----- CC, SX, TI, ST, IT SCAN ----- CC, SX, TI, ST, IT (random display, no answer numbers; SCAN must be entered on the same line as the DISPLAY, e.g., D SCAN or DISPLAY SCAN) STD ----- BIB, IPC, and NCL IABS ----- ABS, indented with text labels IALL ----- ALL, indented with text labels IBIB ----- BIB, indented with text labels IMAX ----- MAX, indented with text labels

OBIB ----- AN, plus Bibliographic Data (original)

ISTD ----- STD, indented with text labels

299 OIBIB ----- OBIB, indented with text labels SBIB ----- BIB, no citations SIBIB ----- IBIB, no citations HIT ----- Fields containing hit terms HITIND ----- IC, ICA, ICI, NCL, CC and index field (ST and IT) containing hit terms HITRN ----- HIT RN and its text modification HITSTR ----- HIT RN, its text modification, its CA index name, and its structure diagram HITSEQ ----- HIT RN, its text modification, its CA index name, its structure diagram, plus NTE and SEQ fields FHITSTR ---- First HIT RN, its text modification, its CA index name, and its structure diagram FHITSEQ ---- First HIT RN, its text modification, its CA index name, its structure diagram, plus NTE and SEQ fields KWIC ----- Hit term plus 20 words on either side OCC ----- Number of occurrence of hit term and field in which it occurs To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDS at an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST; TI, IND; TI, SO. You may specify the format fields in any order and the information will be displayed in the same order as the format specification. All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number. ENTER DISPLAY FORMAT (BIB):bib ANSWER 1 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN L3ΑN 2004:386630 CAPLUS Methods for quantifying ratio between two nucleic acids by NASBA for ΤI diagnosis and treatment of HIV-1, tumor or angiogenic disorders Timmermans, Eveline Catherina Anna Clasina; Van Gemen, Bob IN Primagen Holding B.V., Neth. PASO Eur. Pat. Appl., 32 pp. CODEN: EPXXDW DTPatent LA English FAN.CNT 2 PATENT NO. KIND DATE APPLICATION NO. DATE --------------A1 20040512 EP 2003-78547 20031107 EP 1418242 PΙ R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK A1 20040512 EP 2002-79673 20021108 EP 1418241 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK PRAI EP 2002-79673 20021108 Α

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD RE.CNT 6 ALL CITATIONS AVAILABLE IN THE RE FORMAT

20021108

ANSWER 2 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN L3

P

AN 2004:386629 CAPLUS

US 2002-425055P

- Methods for quantifying ratio between two nucleic acids by NASBA for TI diagnosis and treatment of HIV-1, tumor or angiogenic disorders
- Timmermans, Eveline Catherina Anna Clasina; Van Gemen, Bob IN
- PAPrimagen Holding B.V., Neth.

```
SO
     Eur. Pat. Appl., 37 pp.
     CODEN: EPXXDW
DT
     Patent
     English
LA
FAN.CNT 2
     PATENT NO.
                       KIND DATE
                                             APPLICATION NO. DATE
                       A1
                             20040512
                                             EP 2002-79673
                                                                20021108
PΤ
     EP 1418241
         R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
                            20040512
                                             EP 2003-78547
                                                                20031107
     EP 1418242
                       A1
             AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
              IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     WO 2004042085
                       A2
                            20040521
                                             WO 2003-NL780
                                                                20031107
             AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, EG,
              ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
              KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN,
              MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
              SG, SK, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
              VN, YU, ZA, ZM
         RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE,
              BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU,
              MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN,
             GQ, GW, ML, MR, NE, SN, TD, TG
PRAI EP 2002-79673
                             20021108
                      Α
     US 2002-425055P
                       P
                             20021108
RE.CNT 6
               THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
               ALL CITATIONS AVAILABLE IN THE RE FORMAT
     ANSWER 3 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
L3
     2004:371961 CAPLUS
AN
     Combretastatin A4 phosphate
ΤI
     West, Catharine M. L.; Price, Pat
AU
     Academic Department of Radiation Oncology and Manchester Molecular Imaging
CS
     Centre, University of Manchester, Christie NHS Trust Hospital, Manchester,
     M20 4BX, UK
     Anti-Cancer Drugs (2004), 15(3), 179-187
SO
     CODEN: ANTDEV; ISSN: 0959-4973
     Lippincott Williams & Wilkins
PB
     Journal; General Review
DT
     English
LA
               THERE ARE 83 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE.CNT 83
               ALL CITATIONS AVAILABLE IN THE RE FORMAT
     ANSWER 4 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
L3
     2004:157469 CAPLUS
AN
     140:210743
DN
     Compositions and methods for treating cancer using maytansinoid CD44
ΤI
     antibody immunoconjugates and chemotherapeutic agents
     Adolf, Guenther; Baum, Anke; Heider, Karl-Heinz
IN
     Boehringer Ingelheim International GmbH, Germany
PA
     Eur. Pat. Appl., 52 pp.
SO
     CODEN: EPXXDW
DT
     Patent
LA
     English
FAN.CNT 1
     PATENT NO.
                       KIND DATE
                                             APPLICATION NO.
                       _ _ _ _
                             ----<del>-</del>
PΙ
     EP 1391213
                      A1
                             20040225
                                             EP 2002-18686
                                                                20020821
         R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
              IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
```

OS

L3 AN

DN

TΙ

ΑU

CS

SO

PB DT

LA

 $L_3$ 

AN DN

ΤI

IN PA

SO

DT

LA

PΙ

OS

L3 AN

DN

140:121898

```
WO 2003-EP9166
                                                                   20030819
                               20040304
     WO 2004018000
                         A2
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
              CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
              LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
              PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY,
              KG, KZ, MD, RU
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
                               20020821
PRAI EP 2002-18686
                        Α
     MARPAT 140:210743
               THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE.CNT 22
               ALL CITATIONS AVAILABLE IN THE RE FORMAT
     ANSWER 5 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
     2003:905546 CAPLUS
     140:192442
     Antitumor activity of TZT-1027 (Soblidotin) against vascular endothelial
     growth factor-secreting human lung cancer in vivo
     Natsume, Tsugitaka; Watanabe, Jun-ichi; Koh, Yasuhiro; Fujio, Nami; Ohe,
     Yuichiro; Horiuchi, Toshi; Saijo, Nagahiro; Nishio, Kazuto; Kobayashi,
     Motohiro
     Medicinal Research Department, Teikoku Hormone Mfg. Co., Ltd., Kanagawa,
     213-8522, Japan
     Cancer Science (2003), 94(9), 826-833
     CODEN: CSACCM; ISSN: 1347-9032
     Japanese Cancer Association
     Journal
     English
                THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE.CNT 37
               ALL CITATIONS AVAILABLE IN THE RE FORMAT
     ANSWER 6 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
     2003:836866 CAPLUS
     139:337828
     Preparation of resveratrol and sodium resverastatin phosphate derivatives
     for use in pharmaceutical compositions as antineoplastic and antimicrobial
     agents
     Pettit, George R.; Grealish, Matthew P.
     Arizona Board of Regents, USA
     PCT Int. Appl., 51 pp.
     CODEN: PIXXD2
     Patent
     English
FAN.CNT 1
                        KIND DATE
                                                 APPLICATION NO.
                                                                    DATE
     PATENT NO.
                                                 ______
                        ----
                               _____
      _____
                               20031023
                                                 WO 2003-US11008 20030410
                        A1
     WO 2003086414
          W: CA, JP, US
          RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
               IT, LU, MC, NL, PT, RO, SE, SI, SK, TR
                               20020410
PRAI US 2002-371782P
                         P
     CASREACT 139:337828
                THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE.CNT 10
                ALL CITATIONS AVAILABLE IN THE RE FORMAT
     ANSWER 7 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
      2003:779807 CAPLUS
```

- 299 Ocular neovascularization: a valuable model system TΙ Campochiaro, Peter Anthony; Hackett, Sean Francis AU The Departments of Ophthalmology and Neuroscience, The Johns Hopkins CS University School of Medicine, Baltimore, MD, 21287-9277, USA Oncogene (2003), 22(42), 6537-6548 SO CODEN: ONCNES; ISSN: 0950-9232 Nature Publishing Group PΒ Journal; General Review DTLAEnglish THERE ARE 133 CITED REFERENCES AVAILABLE FOR THIS RECORD RE.CNT 133 ALL CITATIONS AVAILABLE IN THE RE FORMAT ANSWER 8 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN L32003:704282 CAPLUS ΑN DN 140:122251 The vascular targeting agent combretastatin A-4-phosphate induces TI neutrophil recruitment to endothelial cells in vitro Brooks, Andrew C.; Kanthou, Chryso; Cook, Ian H.; Tozer, Gillian M.; AU Barber, Paul R.; Vojnovic, Boris; Nash, Gerard B.; Parkins, Charles S. Tumour Microcirculation Group, Mount Vernon Hospital, Gray Cancer CS Institute, Northwood, Middx., HA6 2JR, UK Anticancer Research (2003), 23(4), 3199-3206 SO CODEN: ANTRD4; ISSN: 0250-7005 International Institute of Anticancer Research PB DT Journal English LΑ THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD RE.CNT 31 ALL CITATIONS AVAILABLE IN THE RE FORMAT ANSWER 9 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN L32003:684303 CAPLUS ΑN 140:52580 DNAntiangiogenesis and radiotherapy: What is the role of combined modality TItreatment? Classen, Johannes; Budach, Wilfried ΑU Dep. Radiation Oncology, Tuebingen University, Tuebingen, D-72076, Germany CS Current Medicinal Chemistry: Anti-Cancer Agents (2003), 3(5), 375-382 SO CODEN: CMCACI; ISSN: 1568-0118 ΡВ Bentham Science Publishers Ltd. Journal: General Review DT T.A English THERE ARE 56 CITED REFERENCES AVAILABLE FOR THIS RECORD RE.CNT 56 ALL CITATIONS AVAILABLE IN THE RE FORMAT ANSWER 10 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN L3 2003:649793 CAPLUS ANDN 140:87178 Efficacy of the tumour vascular targeting agent combretastatin A-4-P at ΤI clinically relevant doses Tozer, G. M.; Honess, D. J.; Wilson, J.; Hill, S. A.; Hodgkiss, R. J.; ΑU Ameer-Beg, S.; Vojnovic, B.; Prise, V. E. Gray Cancer Institute, Mount Vernon Hospital, Northwood, UK CS Microcirculation and Vascular Biology, Meeting of the European Society for SO Microcirculation, 22nd, Exeter, United Kingdom, Aug. 28-30, 2002 (2002), 43-47. Editor(s): Tooke, John; Shore, Angela; Whatmore, Jacqueline. Publisher: Monduzzi Editore, Bologna, Italy. CODEN: 69EIUX; ISBN: 88-323-2828-3
- Conference DT
- English LA
- THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD RE.CNT 5 ALL CITATIONS AVAILABLE IN THE RE FORMAT

299 ANSWER 11 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN 1.3 2003:649791 CAPLUS AN 140:70488 DN Nitrotyrosination of endothelial  $\alpha$ -tubulin: potential effects on TΤ binding of the tumour vascular-targeting agent, combretastatin A-4-P Parkins, C. S.; Cook, I. H.; Kanthou, C.; Mapp, P.; Tozer, G. M. ΑU Tumour Microcirculation Group, Gray Cancer Institute, Northwood, UK CS Microcirculation and Vascular Biology, Meeting of the European Society for SO Microcirculation, 22nd, Exeter, United Kingdom, Aug. 28-30, 2002 (2002), 33-37. Editor(s): Tooke, John; Shore, Angela; Whatmore, Jacqueline. Publisher: Monduzzi Editore, Bologna, Italy. CODEN: 69EIUX; ISBN: 88-323-2828-3 DTConference LΑ English THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD RE.CNT 5 ALL CITATIONS AVAILABLE IN THE RE FORMAT ANSWER 12 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN L3 2003:649789 CAPLUS AN 140:266851 DN Effect of radiation and combretastatin A-4-P on cellular localisation of TI hypoxia inducible factor 1 Dachs, G. U.; Kanthou, C.; Tozer, G. M. ΑU Tumour Microcirculation Group, Gray Cancer Institute, Mount Vernon CS Hospital, Northwood, UK Microcirculation and Vascular Biology, Meeting of the European Society for SO Microcirculation, 22nd, Exeter, United Kingdom, Aug. 28-30, 2002 (2002), 19-23. Editor(s): Tooke, John; Shore, Angela; Whatmore, Jacqueline. Publisher: Monduzzi Editore, Bologna, Italy. CODEN: 69EIUX; ISBN: 88-323-2828-3 DTConference LΑ English THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD RE.CNT 4 ALL CITATIONS AVAILABLE IN THE RE FORMAT ANSWER 13 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN L3 AN2003:535620 CAPLUS 140:12606 DNCombretastatin A-1 phosphate potentiates the antitumour activity of ΤТ cisplatin in a murine adenocarcinoma model Shnyder, S. D.; Cooper, P. A.; Pettit, G. R.; Lippert, J. W., III; Bibby, ΑU M. C. Cancer Research Unit, Tom Connors Cancer Research Centre, University of CS Bradford, Bradford, BD7 1DP, UK Anticancer Research (2003), 23(2B), 1619-1623 SO CODEN: ANTRD4; ISSN: 0250-7005 International Institute of Anticancer Research PB Journal DT English LA RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT ANSWER 14 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN L32003:535566 CAPLUS AN DN 139:390868 Oxi4503, a novel vascular targeting agent: effects on blood flow and TIantitumor activity in comparison to combretastatin A-4 phosphate Hua, Jianyi; Sheng, Yezhou; Pinney, Kevin G.; Garner, Charles M.; Kane, Robert R.; Prezioso, Joseph A.; Pettit, George R.; Chaplin, David J.; Edvardsen, Klaus

Department of Cell and Molecular Biology, Section for Tumor Immunology,

University of Lund, Lund, 22184, Swed.

```
Anticancer Research (2003), 23(2B), 1433-1440
SO
     CODEN: ANTRD4; ISSN: 0250-7005
     International Institute of Anticancer Research
PB
DT
     English
LA
             THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE.CNT 38
             ALL CITATIONS AVAILABLE IN THE RE FORMAT
     ANSWER 15 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
L3
     2003:488339 CAPLUS
AN
DN
     139:390448
     Heme oxygenase and the novel tumour-specific anti-vascular compound
     combretastatin A4-phosphate
     Khelifi, Amel F.; Prise, Vivien E.; Foresti, Roberta; Clark, James E.;
ΑU
     Kanthou, Chryso; Motterlini, Roberto; Tozer, Gillian M.
     Gray Cancer Institute, Mount Vernon Hospital, Northwood, Middlesex, HA6
CS
     2JR, UK
     Heme Oxygenase in Biology and Medicine (2002), 303-312. Editor(s):
SO
     Abraham, Nader G.; Alam, Jawed; Nath, Karl. Publisher: Kluwer
     Academic/Plenum Publishers, New York, N. Y.
     CODEN: 69ECI3; ISBN: 0-306-47264-3
     Conference; General Review
DΤ
     English
LA
              THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE.CNT 50
              ALL CITATIONS AVAILABLE IN THE RE FORMAT
     ANSWER 16 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
L3
     2003:376404 CAPLUS
AN
     138:362737
DN
     Methods for treating neoplastic, angiogenic, vascular, fibroblastic,
TI
     and/or immunosuppressive irregularities of the eye and/or joint via
     administration of combretastatin based medicaments, and iontophoretic
     devices for delivering combretastatin based medicaments
     Parkinson, Thomas M.; Szlek, Malgorzata; Lloyd, Lindsay B.; Vollmer, David
IN
     USA
PA
     U.S. Pat. Appl. Publ., 12 pp.
SO
     CODEN: USXXCO
DT
     Patent
     English
LΑ
FAN.CNT 1
                    KIND DATE
                                         APPLICATION NO. DATE
     PATENT NO.
                    ____
                                          ______
     ______
                                                           20021011
                                         US 2002-270273
     US 2003092774
                     A1
                            20030515
PΤ
PRAI US 2001-330212P P
                          20011017
    MARPAT 138:362737
     ANSWER 17 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
L3
     2003:334852 CAPLUS
AN
     138:353746
DN
     Preparation of stilbenes as vascular targeting agents (VTAs) for treatment
TТ
     of solid tumors and retinal neovascularization.
     Chaplin, David J.; Garner, Charles Manly, III; Kane, Robert Ronald;
IN
     Pinney, Kevin G.; Prezioso, Joseph Anthony
     Oxigene, Inc., USA; Evardsen, Klaus
PA
     PCT Int. Appl., 56 pp.
SO
     CODEN: PIXXD2
DΤ
     Patent
LA
     English
FAN.CNT 1
                                          APPLICATION NO. DATE
                      KIND DATE
     PATENT NO.
```

\_\_\_\_\_\_

ΔIJ

CS

```
WO 2002-US34497 20021028
                              20030501
PΙ
     WO 2003035008
                        Α2
                              20031113
     WO 2003035008
                        Α3
             AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
              CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
              GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
              LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
              PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
              TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
              NE, SN, TD, TG
                                              US 2002-281528
                                                                 20021028
     US 2003149003
                        Α1
                              20030807
                              20011026
PRAI US 2001-337348P
                         Ρ
     MARPAT 138:353746
OS
     ANSWER 18 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
L3
     2003:301800 CAPLUS
AN
DN
     139:159587
     Vascular targeting effect of combretastatin A-4 phosphate dominates the
TΙ
     inherent angiogenesis inhibitory activity
     Ahmed, Bisan; van Eijk, Loes I.; Bouma-ter Steege, Jessica C. A.; van der
AU
     Schaft, Daisy W. J.; van Esch, Anita M.; Joosten-Achjanie, Susan R.;
     Lambin, Philippe; Landuyt, Willy; Griffioen, Arjan W.
     Angiogenesis Laboratory, Research Institute for Growth and Development
CS
      (GROW), Department of Internal Medicine, University Hospital Maastricht,
     Maastricht, 6202 AZ, Neth.
      International Journal of Cancer (2003), 105(1), 20-25
SO
      CODEN: IJCNAW; ISSN: 0020-7136
     Wiley-Liss, Inc.
PΒ
DT
     Journal
     English
               THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE.CNT 33
               ALL CITATIONS AVAILABLE IN THE RE FORMAT
     ANSWER 19 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
L3
AN
      2003:293586 CAPLUS
      139:85159
DN
      Synthesis, in vitro, and in vivo evaluation of phosphate ester derivatives
TI
      of combretastatin A-4
     Hadimani, Mallinath B.; Hua, Jianyi; Jonklaas, M. Devan; Kessler, Raymond
ΔII
      J.; Sheng, Yezhou; Olivares, Adrian; Tanpure, Rajendra P.; Weiser, Aimee;
      Zhang, Jianxing; Edvardsen, Klaus; Kane, Robert R.; Pinney, Kevin G.
      Department of Chemistry & Biochemistry and Center for Drug Discovery,
CS
      Baylor University, Waco, TX, 76798-7348, USA
      Bioorganic & Medicinal Chemistry Letters (2003), 13(9), 1505-1508
SO
      CODEN: BMCLE8; ISSN: 0960-894X
PΒ
      Elsevier Science B.V.
DΤ
      Journal
LA
      English
      CASREACT 139:85159
os
               THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE.CNT 16
               ALL CITATIONS AVAILABLE IN THE RE FORMAT
      ANSWER 20 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
L3
      2003:284080 CAPLUS
AN
      139:285853
DN
      Activity of the vascular targeting agent combretastatin A-4 disodium
TΤ
      phosphate in a xenograft model of AIDS-associated Kaposi's sarcoma
      Rojiani, Amyn M.; Li, Lingyun; Rise, Leroy; Siemann, Dietmar W.
```

Department of Interdisciplinary Oncology and Department of Pathology, H.

AN

DN

2003:145065 CAPLUS

139:288187

```
Lee Moffitt Cancer Center and Research Institute, University of South
    Florida, Tampa, FL, USA
    Acta Oncologica (2002), 41(1), 98-105
SO
    CODEN: ACTOEL; ISSN: 0284-186X
    Taylor & Francis Ltd.
PΒ
     Journal
DT
     English
LA
              THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE.CNT 30
              ALL CITATIONS AVAILABLE IN THE RE FORMAT
    ANSWER 21 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
1.3
     2003:284079 CAPLUS
ΑN
     139:30186
DN
     Preclinical evaluations of therapies combining the vascular targeting
ΤI
     agent combretastatin A-4 disodium phosphate and conventional anticancer
     therapies in the treatment of Kaposi's sarcoma
     Li, Lingyun; Rojiani, Amyn M.; Siemann, Dietmar W.
ΑU
     Department of Pharmacology and Experimental Therapeutics, Shands Cancer
CS
     Center, University of Florida, Gainesville, FL, 32610, USA
     Acta Oncologica (2002), 41(1), 91-97
SO
     CODEN: ACTOEL; ISSN: 0284-186X
     Taylor & Francis Ltd.
PB
     Journal
DT
     English
LA
              THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE.CNT 26
              ALL CITATIONS AVAILABLE IN THE RE FORMAT
     ANSWER 22 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
L3
AN
     2003:202525 CAPLUS
     138:243276
DN
     Vascular implants containing combretastatin A-4 or combretastatin A-4
TI
     phosphate
     Wnendt, Stephan; Chaplin, David; Kuttler, Bernd; Lorenz, Guenter
IN
PA
     Oxygene Inc., USA
     PCT Int. Appl., 61 pp.
SO
     CODEN: PIXXD2
DT
     Patent
LΑ
     German
FAN.CNT 1
                                           APPLICATION NO. DATE
     PATENT NO.
                      KIND DATE
                                           -----
                                                            _____
                      _ - - -
                            _____
                                                            20020903
                                           WO 2002-EP9836
     WO 2003020331
                       A1
                            20030313
PΙ
             AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM,
             HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
             LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL,
             PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA,
             UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ,
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
             CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
             PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
             NE, SN, TD, TG
                            20030320
                                           DE 2001-10142897 20010903
     DE 10142897
                       A1
     DE 10142881
                                           DE 2001-10142881 20010903
                       A1
                            20030403
PRAI DE 2001-10142881 A
                            20010903
     DE 2001-10142897
                      Α
                            20010903
RE.CNT 4
              THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT
     ANSWER 23 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
L3
```

Journal

English

RE.CNT 42

DT

LA

299 ΤI Enhancement of radiation therapy by vascular targeting agents Siemann, Dietmar W.; Horsman, Michael R. ΑU Department of Radiation Oncology, University of Florida Shands Cancer CS Center, Gainesville, FL, 32610, USA Current Opinion in Investigational Drugs (PharmaPress Ltd.) (2002), 3(11), SO 1660-1665 CODEN: COIDAZ; ISSN: 1472-4472 PharmaPress Ltd. PBJournal; General Review DTEnglish LA THERE ARE 56 CITED REFERENCES AVAILABLE FOR THIS RECORD RE.CNT 56 ALL CITATIONS AVAILABLE IN THE RE FORMAT ANSWER 24 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN L32003:115478 CAPLUS AN139:223859 DN Anti-tumor and anti-vascular effects of the novel tubulin-binding agent TT combretastatin A-1 phosphate Holwell, S. E.; Cooper, P. A.; Thompson, M. J.; Pettit, G. R.; Lippert, J. AU W., III; Martin, S. W.; Bibby, M. C. Cancer Research Unit, University of Bradford, West Yorkshire, BD7 1DP, UK CS Anticancer Research (2002), 22(6C), 3933-3940 SO CODEN: ANTRD4; ISSN: 0250-7005 International Institute of Anticancer Research PB DTJournal English LATHERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD RE.CNT 23 ALL CITATIONS AVAILABLE IN THE RE FORMAT ANSWER 25 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN L3 AN 2003:102590 CAPLUS DN 139:254840 Combretastatin A4 Phosphate Has Primary Antineoplastic Activity Against ΤI Human Anaplastic Thyroid Carcinoma Cell Lines and Xenograft Tumors Dziba, Joshua M.; Marcinek, Regina; Venkataraman, Gopalakrishnan; ΑU Robinson, Jill A.; Ain, Kenneth B. Thyroid Cancer Research Laboratory, Medical Service, Veterans Affairs CS Medical Center, and the Dept. of Internal Medicine, University of Kentucky Medical Center, Lexington, KY, USA Thyroid (2002), 12(12), 1063-1070 so CODEN: THYRER; ISSN: 1050-7256 Mary Ann Liebert, Inc. PR DT Journal English LA THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD RE.CNT 18 ALL CITATIONS AVAILABLE IN THE RE FORMAT ANSWER 26 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN L3 2003:13579 CAPLUS ΑN 139:254741 DNMarked potentiation of the antitumour activity of chemotherapeutic drugs TIby the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) Siim, Bronwyn G.; Lee, Alan E.; Shalal-Zwain, Sahar; Pruijn, Frederik B.; AU Wilson, W. R.; Sim, B. G.; McKeage, M. J. Auckland Cancer Society Research Centre, Experimental Oncology Group, The CS University of Auckland, Auckland, N. Z. Cancer Chemotherapy and Pharmacology (2003), 51(1), 43-52 SO CODEN: CCPHDZ; ISSN: 0344-5704 Springer-Verlag PΒ

THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD

### ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
ANSWER 27 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
1.3
     2002:977780 CAPLUS
ΑN
     138:55802
DN
     Preparation of combretastatin A3 diphosphate prodrugs for the treatment of
ΤI
     Pettit, George R.; Minardi, Mathew D.
TN
     Arizona Board of Regents, USA
PΑ
     PCT Int. Appl., 33 pp.
SO
     CODEN: PIXXD2
DТ
     Patent
LA
     English
FAN.CNT 1
                      KIND DATE
                                           APPLICATION NO.
                                                            DATE
     PATENT NO.
                                           ______
                     _ _ _ _
                            ______
                                           WO 2002-US19085 20020617
                     A2
                            20021227
PΙ
     WO 2002102766
                            20030403
                      Α3
     WO 2002102766
         W: CA, JP, US
         RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
             PT, SE, TR
                                           EP 2002-746550
                                                             20020617
                            20040310
     EP 1395265
                       A2
         R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, FI, CY, TR
                                           US 2003-398543
                                                             20030407
     US 2004029838
                       Α1
                            20040212
                            20010615
PRAI US 2001-298606P
                       Р
                       W
                            20020617
     WO 2002-US19085
     ANSWER 28 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
L3
AN
     2002:896045 CAPLUS
DN
     139:374359
     Enhancement of vascular targeting by inhibitors of nitric oxide synthase
TI
     Davis, Peter D.; Tozer, Gillian M.; Naylor, Matthew A.; Thomson, Peter;
ΑU
     Lewis, Gemma; Hill, Sally A.
     Angiogene Pharmaceuticals Ltd., Oxford, OX4 4GA, UK
CS
     International Journal of Radiation Oncology, Biology, Physics (2002),
SO
     54(5), 1532-1536
     CODEN: IOBPD3; ISSN: 0360-3016
     Elsevier Science Inc.
PB
DT
     Journal
     English
              THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE.CNT 18
              ALL CITATIONS AVAILABLE IN THE RE FORMAT
     ANSWER 29 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
L3
     2002:896043 CAPLUS
AN
     139:347507
DN
     Synergy between vascular targeting agents and antibody-directed therapy
TI
     Pedley, R. Barbara; El-Emir, Ethaar; Flynn, Aiden A.; Boxer, Geoffrey M.;
AU
     Dearling, Jason; Raleigh, James A.; Hill, Sally A.; Stuart, Sam; Motha,
     Reeya; Begent, Richard H. J.
     Cancer Research UK Targeting and Imaging Group, Department of Oncology,
CS
     Royal Free and University College Medical School, London, NW3 2PF, UK
     International Journal of Radiation Oncology, Biology, Physics (2002),
SO
     54(5), 1524-1531
     CODEN: IOBPD3; ISSN: 0360-3016
     Elsevier Science Inc.
PΒ
DT
     Journal
     English
LA
              THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE.CNT 36
              ALL CITATIONS AVAILABLE IN THE RE FORMAT
```

AU

- L3ANSWER 30 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN ΔN 2002:896041 CAPLUS DN 139:347506 Combination of vascular targeting agents with thermal or radiation therapy TΙ Horsman, Michael R.; Murata, Rumi ΑU CS Department of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus, DK-8000, Den. SO International Journal of Radiation Oncology, Biology, Physics (2002), 54(5), 1518-1523 CODEN: IOBPD3; ISSN: 0360-3016 Elsevier Science Inc. PΒ DTJournal LA English RE.CNT 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT ANSWER 31 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN T.3 ΑN 2002:896034 CAPLUS DN139:316714 The development of combretastatin A4 phosphate as a vascular targeting TI agent ΑU Chaplin, David J.; Hill, Sally A. CS Oxigene Inc., Watertown, MA, 02472, USA International Journal of Radiation Oncology, Biology, Physics (2002), SO 54(5), 1491-1496 CODEN: IOBPD3; ISSN: 0360-3016 PB Elsevier Science Inc. DTJournal LA English THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD RE.CNT 37 ALL CITATIONS AVAILABLE IN THE RE FORMAT ANSWER 32 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN L3ΑN 2002:816161 CAPLUS DN 138:378695 TΤ The vascular response of tumor and normal tissues on the rat to the vascular targeting agent, combretastatin A-4-phosphate, at clinically relevant doses UΑ Prise, Vivien E.; Honess, Davina J.; Stratford, Michael R. L.; Wilson, John; Tozer, Gillian M. Tumor Microcirculation Group, Gray Cancer Institute, Mount Vernon CS Hospital, Northwood, Middx, HA6 2JR, UK so International Journal of Oncology (2002), 21(4), 717-726 CODEN: IJONES; ISSN: 1019-6439 PB International Journal of Oncology DTJournal LAEnglish RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT L3 ANSWER 33 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN AN 2002:799337 CAPLUS DN 138:381528 TI Application of multiphoton steady state and lifetime imaging to mapping of tumor vascular architecture in vivo
- CS Advanced Technology Dev. Group, Gray Cancer Inst., Northwood, Middlesex, HA6 2JR, UK SO Proceedings of SPIE-The International Society for Optical Engineering

Robert G.; Tozer, Gillian M.; Vojnovic, Borivoj; Wilson, J.

Ameer-Beg, Simon; Barber, Paul R.; Hodqkiss, R. J.; Locke, R. J.; Newman,

(2002), 4620 (Multiphoton Microscopy in the Biomedical Sciences II), 85-95 CODEN: PSISDG; ISSN: 0277-786X

```
SPIE-The International Society for Optical Engineering
PB
DT
     Journal
     English
LA
              THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE.CNT 20
              ALL CITATIONS AVAILABLE IN THE RE FORMAT
     ANSWER 34 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
L3
     2002:794895 CAPLUS
ΑN
     138:297218
DN
     Schedule dependence of combretastatin A4 phosphate in transplanted and
ΤI
     spontaneous tumor models
     Hill, Sally A.; Chaplin, David J.; Lewis, Gemma; Tozer, Gillian M.
AU
     Tumour Microcirculation Group, Gray Cancer Institute, Mount Vernon
CS
     Hospital, Northwood, HA6 2JR, UK
     International Journal of Cancer (2002), 102(1), 70-74
SO
     CODEN: IJCNAW; ISSN: 0020-7136
     Wiley-Liss, Inc.
PΒ
DT
     Journal
LΑ
     English
              THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE.CNT 42
              ALL CITATIONS AVAILABLE IN THE RE FORMAT
     ANSWER 35 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
L3
     2002:755199 CAPLUS
ΑN
DN
     137:284323
     Enzyme-cleavable prodrug compounds
TΙ
     Dubois, Vincent; Fernandez, Anne Marie; Gangwar, Sanjeev; Lewis, Evan;
IN
     Lobl, Thomas J.; Nieder, Matthew H.; Pickford, Lesley B.; Trouet, Andre;
     Yarranton, Geoffrey T.
PA
     Belg.
     U.S. Pat. Appl. Publ., 86 pp., Cont.-in-part of Appl. No. PCT/US99/30393.
SO
     CODEN: USXXCO
DT
     Patent
     English
LΑ
FAN.CNT 3
                      KIND DATE
                                            APPLICATION NO. DATE
     PATENT NO.
                            _____
                                            _____
                       ----
                                                             20010611
                                            US 2001-879442
                            20021003
PΙ
     US 2002142955
                       A1
                                            WO 1999-US30393 19991210
     WO 2000033888
                       A2
                            20000615
                       Α3
                            20011108
     WO 2000033888
             AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
             CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
             IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD,
             MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
             SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
             DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
             CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
                            19981211
PRAI US 1998-111793P
                       P
                       Р
                             19990208
     US 1999-119312P
                       A2
                             19991210
     WO 1999-US30393
                       Р
                             20000614
     US 2000-211887P
                        P
                             20010511
     US 2001-290448P
     MARPAT 137:284323
OS
     ANSWER 36 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
L_3
     2002:736049 CAPLUS
ΔN
DN
     137:253007
     A combination comprising combretastatin and anticancer agents
TI
IN
     Bissery, Marie-Christine
     Aventis Pharma S.A., Fr.
PΑ
```

```
SO
     PCT Int. Appl., 19 pp.
     CODEN: PIXXD2
     Patent
DT
     English
LA
FAN.CNT 1
                                            APPLICATION NO. DATE
                      KIND DATE
     PATENT NO.
                                                              20020315
     WO 2002074229
                       A2
                             20020926
                                            WO 2002-EP3322
PΙ
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ,
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
             CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
                                            US 2002-92508
                                                             20020308
     US 2002183266
                        A1
                             20021205
                                            US 2002-97926
                                                              20020315
                             20030327
     US 2003060429
                        Α1
                                            WO 2002-EP6758
                                                              20020315
                             20040506
     WO 2004037258
                        Α1
             AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
             CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
                                            NO 2003-4022
                                                              20030911
     NO 2003004022
                             20030911
                        Α
PRAI US 2001-275627P
                             20010315
                        Ρ
     WO 2002-EP6758
                             20020315
     ANSWER 37 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
L3
     2002:651667 CAPLUS
ΑN
     138:214971
DN
     Preclinical evaluation of the antitumor activity of the novel
TI
     vascular-targeting agent Oxi 4503
     Hill, Sally A.; Tozer, Gillian M.; Pettit, George R.; Chaplin, David J.
ΑU
     Gray Cancer Institute, Mount Vernon Hospital, Northwood, Middlesex, HA6
CS
     Anticancer Research (2002), 22(3), 1453-1458
SO
     CODEN: ANTRD4; ISSN: 0250-7005
     International Institute of Anticancer Research
PB
DT
     Journal
LΑ
     English
               THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE.CNT 25
              ALL CITATIONS AVAILABLE IN THE RE FORMAT
     ANSWER 38 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
L3
AN
     2002:555278 CAPLUS
     137:119643
DN
     Methods using a combretastatin compound combined with an antitumor agent
ΤI
     for modulating tumor growth and metastasis
     Lee, Francis Y.; Peck, Ronald; Chaplin, David; Pero, Ronald; Edvardsen,
IN
     Klaus
     Bristol-Myers Squibb Company, USA; Oxigene, Inc.
PΑ
SO
     PCT Int. Appl., 69 pp.
     CODEN: PIXXD2
DT
     Patent
LA
     English
FAN.CNT 1
```

L3 AN

DN

2002:419476 CAPLUS

138:32901

```
APPLICATION NO. DATE
                        KIND DATE
     PATENT NO.
                                               ______
                       _ _ _ _
                              _____
                                               WO 2001-US50261 20011220
                              20020725
     WO 2002056692
                       A1
PΙ
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
              CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
              TJ, TM
          RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
              CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
              BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
                                              EP 2001-994435 20011220
     EP 1351573
                         A1
                             20031015
             AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
              IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
                               20001222
PRAI US 2000-258195P
                        P
                               20011220
     WO 2001-US50261
                         W
               THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE.CNT 3
               ALL CITATIONS AVAILABLE IN THE RE FORMAT
     ANSWER 39 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
L3
     2002:471932 CAPLUS
AN
     137:163285
DN
     A phase I pharmacokinetic and translational study of the novel vascular
ΤI
     targeting agent combretastatin A-4 phosphate on a single-dose intravenous
     schedule in patients with advanced cancer
     Dowlati, Afshin; Robertson, Kelly; Cooney, Matthew; Petros, William P.;
ΑU
     Stratford, Michael; Jesberger, John; Rafie, Niusha; Overmoyer, Beth;
     Makkar, Vinit; Stambler, Bruce; Taylor, Anne; Waas, John; Lewin, Jonathan
     S.; McCrae, Keith R.; Remick, Scot C.
     Division of Hematology/Oncology, Department of Medicine, School of
CS
     Medicine, Case Western Reserve University (CWRU), Cleveland, OH, 44106,
     Cancer Research (2002), 62(12), 3408-3416
SO
     CODEN: CNREA8; ISSN: 0008-5472
PΒ
     American Association for Cancer Research
DT
     Journal
     English
LA
               THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE.CNT 14
               ALL CITATIONS AVAILABLE IN THE RE FORMAT
     ANSWER 40 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
L3
      2002:455498 CAPLUS
AN
DN
     Acute effects of vascular modifying agents in solid tumors assessed by
TI
     noninvasive laser doppler flowmetry and near infrared spectroscopy
      Kragh, Michael; Quistorff, Bjorn; Horsman, Michael R.; Kristjansen, Paul
ΑU
      E. G.
      Institute of Molecular Pathology, Panum Institute, University of
CS
      Copenhagen, Copenhagen, DK-2200, Den.
      Neoplasia (New York, NY, United States) (2002), 4(3), 263-267
SO
      CODEN: NEOPFL; ISSN: 1522-8002
      Nature Publishing Group
PB
      Journal
DT
      English
LΑ
                THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE.CNT 39
                ALL CITATIONS AVAILABLE IN THE RE FORMAT
```

ANSWER 41 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN

- TI Combretastatin A-1 phosphate a novel tubulin-binding agent with in vivo anti vascular effects in experimental tumours
- AU Holwell, S. E.; Cooper, P. A.; Grosios, K.; Lippert, J. W., III; Pettit, G. R.; Shnyder, S. D.; Bibby, M. C.
- CS Cancer Research Unit, University of Bradford, Bradford, BD7 1DP, UK
- SO Anticancer Research (2002), 22(2A), 707-711 CODEN: ANTRD4; ISSN: 0250-7005
- PB International Institute of Anticancer Research
- DT Journal
- LA English
- RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT
- L3 ANSWER 42 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
- AN 2002:284300 CAPLUS
- DN 137:149895
- TI Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy
- AU Siemann, Dietmar W.; Mercer, Emma; Lepler, Sharon; Rojiani, Amyn M.
- CS Department of Radiation Oncology, Shands Cancer Center, University of Florida, Gainesville, FL, 32610, USA
- SO International Journal of Cancer (2002), 99(1), 1-6 CODEN: IJCNAW; ISSN: 0020-7136
- PB Wiley-Liss, Inc.
- DT Journal
- LA English
- RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT
- L3 ANSWER 43 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
- AN 2002:257650 CAPLUS
- DN 137:241782
- TI Differential sensitivity of two adenocarcinoma xenografts to the anti-vascular drugs combretastatin A4 phosphate and 5,6-dimethylxanthenone-4-acetic acid, assessed using MRI and MRS
- AU Beauregard, Daniel A.; Pedley, R. Barbara; Hill, Sally A.; Brindle, Kevin M.
- CS Department of Biochemistry, University of Cambridge, Cambridge, CB2 1GA, UK
- SO NMR in Biomedicine (2002), 15(2), 99-105 CODEN: NMRBEF; ISSN: 0952-3480
- PB John Wiley & Sons Ltd.
- DT Journal
- LA English
- RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT
- L3 ANSWER 44 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
- AN 2002:257649 CAPLUS
- DN 137:241613
- TI Evaluation of the anti-vascular effects of combretastatin in rodent tumours by dynamic contrast enhanced MRI
- AU Maxwell, Ross J.; Wilson, John; Prise, Vivien E.; Vojnovic, Borivoj; Rustin, Gordon J.; Lodge, Martin A.; Tozer, Gillian M.
- CS Mount Vernon Hospital, Gray Cancer Institute, Northwood, Middlesex, HA6 2JR, UK
- SO NMR in Biomedicine (2002), 15(2), 89-98 CODEN: NMRBEF; ISSN: 0952-3480
- PB John Wiley & Sons Ltd.
- DT Journal
- LA English
- RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD

## ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
ANSWER 45 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
L3
     2002:220602 CAPLUS
AN
     136:268115
DN
     Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts,
ΤI
     mono- and di- amino acid salts, and mono- and di-amino acid ester salts
     Venit, John J.; Dali, Mandar V.; Dali, Manisha M.; Huang, Yande; Dahlheim,
IN
     Charles E.; Tejwani, Ravindra W.
     Bristol-Myers Squibb Company, USA
PA
     PCT Int. Appl., 84 pp.
SO
     CODEN: PIXXD2
     Patent
DT
     English
LA
FAN.CNT 1
                                           APPLICATION NO.
                                                             DATE
                      KIND DATE
     PATENT NO.
                      _ _ _ _
     WO 2002022626
                       A1
                            20020321
                                           WO 2001-US28401 20010912
PΙ
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,
             PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,
             US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
                            20020613
                                           US 2001-950500
                                                             20010911
     US 2002072507
                       Α1
                            20031230
     US 6670344
                       B2
                                            AU 2001-90771
                                                             20010912
                            20020326
     AU 2001090771
                       Α5
                                            BR 2001-7210
                                                             20010912
                            20030225
     BR 2001007210
                       Α
                            20030616
                                            EE 2002-249
                                                             20010912
     EE 200200249
                       Α
                                            EP 2001-970806
                                                             20010912
     EP 1320534
                            20030625
                       Α1
             AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
         R:
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
                                            JP 2002-526877
                                                             20010912
                       T2
                            20040325
     JP 2004509128
     NO 2002002270
                            20020701
                                            NO 2002-2270
                                                             20020513
                       Α
                            20040318
                                            US 2003-660439
                                                             20030910
     US 2004054212
                       Α1
PRAI US 2000-232568P
                       Ρ
                            20000914
                       Ρ
                             20001207
     US 2000-251921P
                       A1
                             20010911
     US 2001-950500
     WO 2001-US28401
                       W .
                            20010912
     MARPAT 136:268115
              THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE.CNT 3
              ALL CITATIONS AVAILABLE IN THE RE FORMAT
     ANSWER 46 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
L3
     2002:219473 CAPLUS
AN
DN
     137:119212
     The tumor vascular targeting agent combretastatin A-4-phosphate induces
ΤI
     reorganization of the actin cytoskeleton and early membrane blebbing in
     human endothelial cells
     Kanthou, Chryso; Tozer, Gillian M.
ΑU
     Tumour Microcirculation Group, Gray Cancer Institute, Middlesex, HA6 2JR,
CS
     Blood (2002), 99(6), 2060-2069
SO
     CODEN: BLOOAW; ISSN: 0006-4971
     American Society of Hematology
PB
DT
     Journal
LA
     English
              THERE ARE 67 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE.CNT 67
```

```
ANSWER 47 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
L3
     2002:180157 CAPLUS
AN
     138:55697
DN
     Synthesis of disodium combretastatin A-4 3'-O-phosphate
TI
     Zhao, Huiping; Chen, Guorong; Li, Yuanchao
ΑU
     Department of Fine Chemistry, East China University of Science +
CS
     Technology, Shanghai, 200237, Peop. Rep. China
     Zhongguo Yiyao Gongye Zazhi (2001), 32(12), 531-532, 535
SO
     CODEN: ZYGZEA; ISSN: 1001-8255
     Zhongguo Yiyao Gongye Zazhi Bianjibu
PB
DТ
     Journal
     Chinese
LA
os
     CASREACT 138:55697
     ANSWER 48 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
L3
     2002:157495 CAPLUS
AN
     136:205412
DN
     Oligopeptide-based prodrugs activated by plasmin and their use in cancer
тT
     chemotherapy
     Trouet, Andre; Dubois, Vincent; Passioukov, Alexandre
IN
     Coulter Pharmaceutical, Inc., USA
PΑ
SO
     PCT Int. Appl., 67 pp.
     CODEN: PIXXD2
DT
     Patent
LA
     English
FAN.CNT 1
     PATENT NO.
                      KIND
                            DATE
                                           APPLICATION NO. DATE
                                                             _ _ _ _ _ _ _
                      _ _ _ _
                                           WO 2001-US26476 20010823
     WO 2002015700
                            20020228
PΙ
                       A1
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
             RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,
             UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
                                           AU 2001-86727
                                                             20010823
                       A5
                            20020304
     AU 2001086727
PRAI US 2000-227686P
                       Ρ
                            20000824
     WO 2001-US26476
                       W
                            20010823
os
     MARPAT 136:205412
              THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE.CNT
              ALL CITATIONS AVAILABLE IN THE RE FORMAT
     ANSWER 49 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
L3
     2002:151298 CAPLUS
ΑN
DN
     137:288554
     The influence of combretastatin A-4 and vinblastine on interstitial fluid
TT
     pressure in BT4An rat gliomas
     Eikesdal, Hans Petter; Landuyt, Willy; Dahl, Olav
ΑU
     Department of Oncology, University of Bergen, Haukeland University
CS
     Hospital, Bergen, 5021, Norway
     Cancer Letters (Shannon, Ireland) (2002), 178(2), 209-217
SO
     CODEN: CALEDQ; ISSN: 0304-3835
     Elsevier Science Ireland Ltd.
PΒ
DT
     Journal
LA
     English
              THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE.CNT
       48
```

```
L3
      ANSWER 50 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
AN
      2002:142717 CAPLUS
DN
      136:183937
      Preparation and use of cis-stilbene derivatives with vascular damaging
ΤI
      activity
IN
      Davis, Peter David
      Angiogene Pharmaceuticals Ltd., UK
PA
      PCT Int. Appl., 21 pp.
so
      CODEN: PIXXD2
      Patent
DT
LΑ
      English
FAN.CNT 1
                         KIND DATE
                                                  APPLICATION NO.
                                                                      DATE
      PATENT NO.
      _____
                                -----
                                                  _____
                                                                     _____
                                                 WO 2001-GB3668
      WO 2002014329
                                20020221
                                                                      20010815
                         A1
PΙ
          W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
               SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
          RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
               DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
               BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
                                                AU 2001-77629
                                                                      20010815
                          A5
                                 20020225
      AU 2001077629
                                                  EP 2001-955467
                                                                      20010815
                                 20030521
                           A1
      EP 1311514
               AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
               IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
                                                 US 2003-367606
                                                                      20030214
      US 2003181424
                         A1
                                 20030925
                                 20000815
PRAI GB 2000-19944
                           Α
                                 20010815
                           W
      WO 2001-GB3668
      MARPAT 136:183937
OS
                THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE.CNT 7
                ALL CITATIONS AVAILABLE IN THE RE FORMAT
      ANSWER 51 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
L3
      2002:72094 CAPLUS
AN
      136:134622
DN
      Methods of synthesizing prodrugs of combretastatin A-4
ΤI
      Seyedi, Faye; Gale, Jonathan; Haider, Reem; Hoare, John
IN
      Oxigene, Inc., USA
PA
      PCT Int. Appl., 41 pp.
SO
      CODEN: PIXXD2
DT
      Patent
LA
      English
FAN.CNT 1
      PATENT NO.
                         KIND DATE
                                                  APPLICATION NO.
                                                                      DATE
                          ----
                                                  -----
      ______
                                                  WO 2001-US22403 20010717
                          A1
                                 20020124
PΙ
      WO 2002006279
                          C1
                                 20020418
      WO 2002006279
                          C2
                                 20030403
      WO 2002006279
               AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
               CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
               GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
               LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
           RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
               DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
                                                 US 2001-908321 20010717
      US 2002119951
                          A1
                                 20020829
PRAI US 2000-218766P
                           Ρ
                                 20000717
```

```
OS
     CASREACT 136:134622
     ANSWER 52 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
L3
     2002:10314 CAPLUS
AN
     136:86054
DN
     Tripeptide prodrug compounds
ΤI
     Bebbington, Christopher R.; Dubois, Vincent; Gangwar, Sanjeev; Lobl,
IN
     Thomas J.; Nieder, Matthew H.; Pickford, Leslie B.; Trouet, Andre;
      Yarranton, Geoffrey T.
     Corixa Corporation, USA
PΑ
      PCT Int. Appl., 102 pp.
SO
      CODEN: PIXXD2
      Patent
DT
LΑ
     English
FAN.CNT 1
                                                 APPLICATION NO. DATE
                         KIND DATE
      PATENT NO.
                                                 ______
                         ____
                                _____
                          A2
                                20020103
                                                 WO 2001-US40925 20010611
ΡI
      WO 2002000263
      WO 2002000263
                         A3
                                20020815
              AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
               CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
               LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO,
               RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,
               VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
          RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
               DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
               BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
                                                EP 2001-942249 20010611
                          A2 20030326
      EP 1294403
               AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
               IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
      JP 2004501875
                                20040122
                                                JP 2002-505044
                                                                     20010611
                          Т2
                                                 US 2002-311519
                                                                     20021213
      US 2003181359
                                20030925
                          A1
PRAI US 2000-212880P
                                20000614
                          Р
                          W
                                20010611
      WO 2001-US40925
      CASREACT 136:86054; MARPAT 136:86054
os
      ANSWER 53 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
L3
AN
      2001:923644 CAPLUS
DN
      136:58787
      Enzyme-cleavable prodrug compounds
TΙ
      Nieder, Matthew H.; Dubois, Vincent; Gangwar, Sanjeev; Lobl, Thomas J.;
IN
      Pickford, Leslie B.; Trouet, Andre; Yarranton, Geoffrey T.
      Corixa Corporation, USA
PA
      PCT Int. Appl., 159 pp.
SO
      CODEN: PIXXD2
DT
      Patent
LA
      English
FAN.CNT 3
                                                 APPLICATION NO.
                                                                    DATE
                         KIND DATE
      PATENT NO.
                         ---
                                _____
      _____
                         A2
                                                 WO 2001-US18903 20010611
      WO 2001095945
                                20011220
PΙ
                         A3
                                20020815
      WO 2001095945
              AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
               CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
               RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
          RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
               BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
```

L3

ΑN

2001:853282 CAPLUS

```
EP 2001-950291
                                                             20010611
                       A2
                            20030326
     EP 1294405
         R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
                                            JP 2002-510122
                                                             20010611
     JP 2004510703
                            20040408
                       T2
                            20000614
PRAI US 2000-211887P
                       P
                            20010511
     US 2001-290448P
                       Р
     WO 2001-US18903
                       W .
                            20010611
     MARPAT 136:58787
os
     ANSWER 54 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
T.3
     2001:923642 CAPLUS
ΑN
     136:74618
DN
     Prodrug compounds with isoleucine
TI
     Pickford, Lesley B.; Gangwar, Sanjeev; Lobl, Thomas J.; Nieder, Matthew
IN
     H.; Yarranton, Geoffrey T.
     Corixa Corporation, USA
PA
     PCT Int. Appl., 107 pp.
SO
     CODEN: PIXXD2
DT
     Patent
LΑ
     English
FAN.CNT 1
                                            APPLICATION NO. DATE
                      KIND DATE
     PATENT NO.
                                            ._____
                                                             _____
                      _ _ _ _ _
     _____
                                            WO 2001-US18857 20010611
                       A2
                             20011220
PΙ
     WO 2001095943
                       A3
                             20020829
     WO 2001095943
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
             RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,
             UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
                                            EP 2001-944442
                                                            20010611
                       A2
                            20030326
     EP 1294404
             AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
                                            JP 2002-510120
                                                              20010611
     JP 2004510702
                       T2 -
                             20040408
                                            US 2002-311411
                                                              20021213
                             20040226
     US 2004039160
                       A1
                             20000614
PRAI US 2000-211686P
                       Р
                       W
                             20010611
     WO 2001-US18857
OS
     MARPAT 136:74618
     ANSWER 55 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
L3
     2001:864436 CAPLUS
AN
     137:119128
DN
     Tumor vasculature is targeted by the combination of combretastatin A-4 and
TI
     hyperthermia
     Eikesdal, Hans Peter; Bjerkvig, Rolf; Raleigh, James A.; Mella, Olav;
AU
     Dahl, Olav
     Department of Oncology, University of Bergen, Haukeland University
CS
     Hospital, Bergen, 5021, Norway
     Radiotherapy and Oncology (2001), 61(3), 313-320
SO
     CODEN: RAONDT; ISSN: 0167-8140
PΒ
     Elsevier Science Ireland Ltd.
DT
     Journal
     English
LA
               THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE.CNT 49
               ALL CITATIONS AVAILABLE IN THE RE FORMAT
```

ANSWER 56 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN

DN

TI

135:331299

antimicrobial agents

```
DN
     Study of the anticancer effects of the vascular targeting agent
ΤI
     combretastatin A-4 disodium phosphate
     Li, Lingyun
ΑU
     Univ. of Florida, Gainesville, FL, USA
CS
     (2000) 127 pp. Avail.: UMI, Order No. DA9997827
SO
     From: Diss. Abstr. Int., B 2001, 61(12), 6410
     Dissertation
DT
     English
LΑ
     ANSWER 57 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
L3
     2001:811045 CAPLUS
AN
     137:43550
DN
     Combretastatin A-4 disodium phosphate: a vascular targeting agent that
ΤT
     improves the anti-tumor effects of hyperthermia, radiation, and mild
     thermoradiotherapy
     Murata, Rumi; Overgaard, Jens; Horsman, Michael R.
ΑU
     Department of Experimental Clinical Oncology, Aarhus University Hospital,
CS
     Danish Cancer Society, Aarhus, Den.
     International Journal of Radiation Oncology, Biology, Physics (2001),
SO
     51(4), 1018-1024
     CODEN: IOBPD3; ISSN: 0360-3016
     Elsevier Science Inc.
PB
     Journal
DΤ
LA
     English
              THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE.CNT 38
              ALL CITATIONS AVAILABLE IN THE RE FORMAT
     ANSWER 58 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
L3
     2001:798232 CAPLUS
AN
DN
     135:344595
     Preparation of combretastatin A-1 phosphate and combretastatin B-1
ΤI
     phosphate prodrugs with increased solubility
     Pettit, George R.; Lippert, John W., III
IN
     Arizona Board of Regents, A Body Corporate of the State of Arizona, Acting
PΑ
     for and On Behalf of Arizona State University, USA
     PCT Int. Appl., 41 pp.
SO
     CODEN: PIXXD2
DT
     Patent
LΑ
     English
FAN.CNT 1
                                           APPLICATION NO.
                                                             DATE
                      KIND DATE
     PATENT NO.
                                            ______
                       _ - - -
                            _____
                                            WO 2001-US13858 20010427
                             20011101
     WO 2001081355
                       A1
PΙ
         W: CA, JP, US
         RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
              PT, SE, TR
                             20030129
                                            EP 2001-928978
                                                             20010427
     EP 1278758
                       Α1
             AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
              IE, FI, CY, TR
                                            US 2002-258672
                                                             20021025
                             20031127
     US 2003220298
                       Α1
                        Ρ
                             20000427
PRAI US 2000-200395P
     WO 2001-US13858
                       W
                             20010427
     CASREACT 135:344595
OS
               THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE.CNT 11
               ALL CITATIONS AVAILABLE IN THE RE FORMAT
     ANSWER 59 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
L_3
ΑN
     2001:798176 CAPLUS
```

Synthesis of hydroxyphenstatin and the prodrugs thereof as anticancer and

ΑN

DN

ΤI

2001:612313 CAPLUS

136:31380

```
Pettit, George R.; Grealish, Matthew P.
IN
    Arizona Board of Regents, A Body Corporate of the State of Arizona, Acting
PA
    for and On Behalf of Arizona State University, USA
    PCT Int. Appl., 40 pp.
SO
    CODEN: PIXXD2
DT
    Patent
    English
LA
FAN.CNT 1
                     KIND DATE
                                           APPLICATION NO.
                                                            DATE
    PATENT NO.
                                           _____
                                           WO 2001-US13731 20010427
    WO 2001081288
                            20011101
                      A1
PΙ
         W: CA, JP, US
         RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
             PT, SE, TR
                                           EP 2001-930892
                                                            20010427
                            20030409
     EP 1299337
                      Α1
         R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, FI, CY, TR
     US 2003220304
                            20031127
                                           US 2003-258676
                                                            20030424
                      A1
PRAI US 2000-200394P
                       Р
                            20000427
     WO 2001-US13731
                       W
                            20010427
    MARPAT 135:331299
OS
              THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE.CNT 3
              ALL CITATIONS AVAILABLE IN THE RE FORMAT
     ANSWER 60 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
L3
     2001:712132 CAPLUS
AN
DN
     136:79365
     The susceptibility of tumors to the antivascular drug combretastatin A4
ΤI
     phosphate correlates with vascular permeability
     Beauregard, Daniel A.; Hill, Sally A.; Chaplin, Dai J.; Brindle, Kevin M.
AU
     Department of Biochemistry, University of Cambridge, Cambridge, CB2 1GA,
CS
     IJK
     Cancer Research (2001), 61(18), 6811-6815
SO
     CODEN: CNREA8; ISSN: 0008-5472
     American Association for Cancer Research
PB
     Journal
DT
     English
LA
              THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE.CNT 30
              ALL CITATIONS AVAILABLE IN THE RE FORMAT
     ANSWER 61 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
L3
     2001:659027 CAPLUS
ΔN
     136:295
DN
     Mechanisms associated with tumor vascular shut-down induced by
TI
     combretastatin A-4 phosphate: intravital microscopy and measurement of
     vascular permeability
     Tozer, Gillian M.; Prise, Vivien E.; Wilson, John; Cemazar, Maja; Shan,
ΑU
     Siging; Dewhirst, Mark W.; Barber, Paul R.; Vojnovic, Borivoj; Chaplin,
     David J.
     Gray Cancer Institute, Mount Vernon Hospital, Northwood, HA6 2JR, UK
CS
     Cancer Research (2001), 61(17), 6413-6422
SO
     CODEN: CNREA8; ISSN: 0008-5472
     American Association for Cancer Research
PΒ
     Journal
DT
     English
LA
              THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE.CNT 42
              ALL CITATIONS AVAILABLE IN THE RE FORMAT
     ANSWER 62 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
1,3
```

Antineoplastic agents 463. Synthesis of combretastatin A-3 diphosphate

RE.CNT 5

prodrugs Pettit, George R.; Minardi, Mathew D.; Boyd, Michael R.; Pettit, Robin K. AU Cancer Research Institute and Department of Chemistry and Biochemistry, CS Arizona State University, Tempe, AZ, 85287-2404, USA Anti-Cancer Drug Design (2001), Volume Date 2000, 15(6), 397-403 SO CODEN: ACDDEA; ISSN: 0266-9536 Oxford University Press PB Journal DTEnglish ΤÃ THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD RE.CNT 33 ALL CITATIONS AVAILABLE IN THE RE FORMAT ANSWER 63 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN L3 ΑN 2001:483534 CAPLUS 136:318886 DN Interaction between combretastatin A-4 disodium phosphate and radiation in TTmurine tumors Murata, R.; Siemann, D. W.; Overgaard, J.; Horsman, M. R. ΑU Danish Cancer Society, Department of Experimental Clinical Oncology, CS Aarhus University Hospital, Aarhus, DK-8000, Den. Radiotherapy and Oncology (2001), 60(2), 155-161 SO CODEN: RAONDT; ISSN: 0167-8140 Elsevier Science Ireland Ltd. PB DTJournal English LATHERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD RE.CNT 26 ALL CITATIONS AVAILABLE IN THE RE FORMAT ANSWER 64 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN L3 2001:465870 CAPLUS AN 135:238667 DN Eradication of colorectal xenografts by combined radioimmunotherapy and TTcombretastatin A-4 3-0-phosphate Pedley, R. Barbara; Hill, Sally A.; Boxer, Geoffrey M.; Flynn, Aiden A.; ΑIJ Boden, Robert; Watson, Rebecca; Dearling, Jason; Chaplin, David J.; Begent, Richard H. J. Department of Oncology, Royal Free and University College Medical School, CS London, NW3 2PF, UK Cancer Research (2001), 61(12), 4716-4722 SO CODEN: CNREA8; ISSN: 0008-5472 American Association for Cancer Research PB DTJournal LA English THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD RE.CNT 33 ALL CITATIONS AVAILABLE IN THE RE FORMAT ANSWER 65 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN L3 2001:379423 CAPLUS ΑN 135:189977 DNSpecific targeting of cytosine deaminase to solid tumors by engineered TI Clostridium acetobutylicum Theys, Jan; Landuyt, Willy; Nuyts, Sandra; Van Mellaert, Lieve; Van ΑU Oosterom, Allan; Lambin, Philippe; Anne, Jozef Laboratory of Bacteriology, Rega Institute for Medical Research, Louvain, CS B-3000, Belg. Cancer Gene Therapy (2001), 8(4), 294-297 SO CODEN: CGTHEG; ISSN: 0929-1903 Nature America Inc. PR DT Journal LΑ English

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD

- ANSWER 66 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN L3 ΑN 2001:294493 CAPLUS DN 135:220760 Effects of combretastatin A4 phosphate on endothelial cell morphology in TI vitro and relationship to tumor vascular targeting activity in vivo Galbraith, Susan M.; Chaplin, David J.; Lee, Francesca; Stratford, Michael ΑU R. L.; Locke, Rosalind J.; Vojnovic, Borivoj; Tozer, Gillian M. Tumour Microcirculation Group, Gray Laboratory Cancer Research Trust, CS Northwood, HA6 2JR, UK Anticancer Research (2001), 21(1A), 93-102 SO CODEN: ANTRD4; ISSN: 0250-7005 PB International Institute of Anticancer Research DTJournal English LA THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD RE.CNT 42 ALL CITATIONS AVAILABLE IN THE RE FORMAT ANSWER 67 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN L3 2001:285856 CAPLUS AN135:251511 DN Combretastatin-A4 disrupts neovascular development in non-neoplastic TI tissue Griggs, J.; Hesketh, R.; Smith, G. A.; Brindle, K. M.; Metcalfe, J. C.; ΑU Thomas, G. A.; Williams, E. D. Department of Biochemistry, University of Cambridge, Cambridge, CB2 1QW, CS British Journal of Cancer (2001), 84(6), 832-835 SO CODEN: BJCAAI; ISSN: 0007-0920 Harcourt Publishers Ltd. PBDTJournal LA English THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD RE.CNT 19 ALL CITATIONS AVAILABLE IN THE RE FORMAT ANSWER 68 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN L3AN 2001:175425 CAPLUS DN134:348060 Comparative effects of combretastatin A-4 disodium phosphate and ΤI 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues Murata, R.; Overgaard, J.; Horsman, M. R. ΑU Danish Cancer Society, Department of Experimental Clinical Oncology, CS Aarhus University Hospital, Aarhus, DK-8000, Den. International Journal of Radiation Biology (2001), 77(2), 195-204 SO CODEN: IJRBE7; ISSN: 0955-3002 Taylor & Francis Ltd. PR DT Journal English LA RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT
- L3 ANSWER 69 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
- AN 2001:125583 CAPLUS
- DN 134:348034
- TI Evaluation of combretastatin A-4 prodrug in a non-Hodgkin's lymphoma xenograft model: preclinical efficacy
- AU Nabha, Sanaa M.; Mohammad, Ramzi M.; Wall, Nathan R.; Dutcher, Julie A.; Salkini, Bashar M.; Pettit, George R.; Al-Katib, Ayad M.
- CS Division of Hematology and Oncology, Department of Internal Medicine, School of Medicine, Wayne State University, Detroit, MI, 48201, USA
- SO Anti-Cancer Drugs (2001), 12(1), 57-63

2000:757705 CAPLUS

134:51116

AN DN

ΤI

CODEN: ANTDEV; ISSN: 0959-4973 Lippincott Williams & Wilkins PB Journal DT English LA THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD RE.CNT 23 ALL CITATIONS AVAILABLE IN THE RE FORMAT ANSWER 70 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN  $L_3$ AN 2001:113357 CAPLUS 135:189844 DN In vivo antitumor effect of vascular targeting combined with either TΙ ionizing radiation or anti-angiogenesis treatment Landuyt, W.; Ahmed, B.; Nuyts, S.; Theys, J.; Op de Beeck, M.; Rijnders, ΑU A.; Anne, J.; van Oosterom, A.; Van den Bogaert, W.; Lambin, P. Laboratory of Experimental Radiobiology, Katholieke Universiteit, Louvain, CS Belg. International Journal of Radiation Oncology, Biology, Physics (2001), SO 49(2), 443-450 CODEN: IOBPD3; ISSN: 0360-3016 Elsevier Science Inc. PB DT Journal English LATHERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD RE.CNT 34 ALL CITATIONS AVAILABLE IN THE RE FORMAT ANSWER 71 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN L3 AN2001:113153 CAPLUS DN 134:320618 Improvement of Clostridium tumor targeting vectors evaluated in rat TIrhabdomyosarcomas Theys, J.; Landuyt, W.; Nuyts, S.; Van Mellaert, L.; Bosmans, E.; ΑU Rijnders, A.; Van Den Bogaert, W.; van Oosterom, A.; Anne, J.; Lambin, P. Laboratory of Bacteriology, Rega Institute for Medical Research, K.U. CS Leuven, Louvain, B-3000, Belg. FEMS Immunology and Medical Microbiology (2001), 30(1), 37-41 SO CODEN: FIMIEV; ISSN: 0928-8244 PΒ Elsevier Science B.V. DTJournal LA English THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD RE.CNT 18 ALL CITATIONS AVAILABLE IN THE RE FORMAT ANSWER 72 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN L3 2001:35285 CAPLUS AN 135:70797 DN Combretastatin A-4 and doxorubicin combination treatment is effective in a TI preclinical model of human medullary thyroid carcinoma Nelkin, Barry D.; Ball, Douglas W. ΑU Department of Oncology, Johns Hopkins University School of Medicine, CS Baltimore, MD, 21231, USA Oncology Reports (2001), 8(1), 157-160 SO CODEN: OCRPEW; ISSN: 1021-335X PΒ Oncology Reports DTJournal LA English THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD RE.CNT 17 ALL CITATIONS AVAILABLE IN THE RE FORMAT ANSWER 73 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN L3

Antineoplastic agents 429. Syntheses of the combretastatin A-1 and

-----

WO 2000048606

ΡI

```
combretastatin B-1 prodrugs
     Pettit, George R.; Lippert, John W., III
ΑU
     Cancer Research Institute and Department of Chemistry and Biochemistry,
CS
     Arizona State University, Tempe, AZ, 85287-2404, USA
     Anti-Cancer Drug Design (2000), 15(3), 203-216
SO
     CODEN: ACDDEA; ISSN: 0266-9536
     Oxford University Press
PΒ
     Journal
דת
LA
     English
              THERE ARE 94 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE.CNT 94
              ALL CITATIONS AVAILABLE IN THE RE FORMAT
     ANSWER 74 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
L3
AN
     2000:717223 CAPLUS
     134:216909
DN
     Determinants of anti-vascular action by combretastatin A-4 phosphate: role
TT
     of nitric oxide
     Parkins, C. S.; Holder, A. L.; Hill, S. A.; Chaplin, D. J.; Tozer, G. M.
AU
     Tumour Microcirculation Group, Gray Laboratory Cancer Research Trust,
CS
     Mount Vernon Hospital, Northwood, HA6 2JR, UK
     British Journal of Cancer (2000), 83(6), 811-816
SO
     CODEN: BJCAAI; ISSN: 0007-0920
     Harcourt Publishers Ltd.
PΒ
DT
     Journal
     English
LA
              THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE.CNT 33
              ALL CITATIONS AVAILABLE IN THE RE FORMAT
     ANSWER 75 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
T.3
     2000:619056 CAPLUS
ΑN
     134:246933
DN
     Vascular targeting of solid tumors: a major 'inverse' volume-response
TI
     relationship following combretastatin A-4 phosphate treatment of rat
     rhabdomyosarcomas
     Landuyt, W.; Verdoes, O.; Darius, D. O.; Drijkoningen, M.; Nuyts, S.;
ΑU
     Theys, J.; Stockx, L.; Wynendaele, W.; Fowler, J. F.; Maleux, G.; Van den
     Bogaert, W.; Anne, J.; van Oosterom, A.; Lambin, P.
     Department of Experimental Radiobiology/Radiotherapy, Catholic University
CS
     of Leuven (KULeuven), University Hospital Gasthuisberg, Louvain, B-3000,
     European Journal of Cancer (2000), 36(14), 1833-1843
SO
     CODEN: EJCAEL; ISSN: 0959-8049
     Elsevier Science Ltd.
PΒ
DT
     Journal
LA
     English
              THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE.CNT 38
              ALL CITATIONS AVAILABLE IN THE RE FORMAT
     ANSWER 76 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
L3
     2000:592560 CAPLUS
AN
DN
     133:198575
     Compositions and methods for use in targeting vascular destruction
ΤI
IN
     Pero, Ronald W.; Sherris, David
PA
     Oxigene, Inc., USA
SO
     PCT Int. Appl., 36 pp.
     CODEN: PIXXD2
DΤ
     Patent
LA
     English
FAN.CNT 1
                                            APPLICATION NO. DATE
     PATENT NO.
                      KIND DATE
```

\_ \_ **\_ \_ \_ \_ \_ \_** \_

20000824

Α1

WO 2000-US3996

20000216

DN

133:207722

```
AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,
             DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN,
             IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
             MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
             SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
             CG, CI, CM, GA, GN, GW,
                                     ML, MR, NE, SN, TD, TG
                             20000824
                                            CA 2000-2358925
     CA 2358925
                       AA
                                                              20000216
                                                              20000216
                             20011114
                                            EP 2000-914606
     EP 1152764
                       Α1
             AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO
     JP 2002537262
                        T2
                             20021105
                                            JP 2000-599398
                                                              20000216
                                            US 2000-505402
     US 6538038
                        В1
                             20030325
                                                              20000216
                                            US 2002-218833
     US 2003109500
                        Α1
                             20030612
                                                              20020814
PRAI US 1999-120478P
                        Ρ
                             19990218
     US 2000-505402
                       A1
                             20000216
     WO 2000-US3996
                        W
                             20000216
os
     MARPAT 133:198575
              THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE.CNT
       1
              ALL CITATIONS AVAILABLE IN THE RE FORMAT
     ANSWER 77 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
L3
                  CAPLUS
     2000:592549
AN
     133:172166
DN
ΤI
     Combinations for the treatment of diseases involving angiogenesis
IN
     Davis, Peter David
PA
     Angiogene Pharmaceuticals Ltd., UK
SO
     PCT Int. Appl., 18 pp.
     CODEN: PIXXD2
DT
     Patent
LA
     English
FAN.CNT 1
     PATENT NO.
                      KIND DATE
                                            APPLICATION NO. DATE
     ______
                      ----
                            _____
                                            _____
                                                              _____
PΙ
     WO 2000048591
                      A1
                             20000824
                                            WO 2000-GB511
                                                             20000215
             AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
             CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
             IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
             MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
             SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
             DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
             CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
                                            BR 2000-8254
     BR 2000008254
                             20011106
                                                              20000215
                       Α
                             20011212
     EP 1161235
                       A1
                                            EP 2000-903832
                                                              20000215
             AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO
                                            JP 2000-599383
     JP 2002537251
                       T2
                             20021105
                                                              20000215
     NZ 513429
                        Α
                             20031031
                                            NZ 2000-513429
                                                              20000215
                                            ZA 2001-6688
     ZA 2001006688
                       Α
                             20020814
                                                              20010814
                             20011015
                                            NO 2001-3966
                                                              20010815
     NO 2001003966
                       Α
PRAI GB 1999-3404
                       Α
                             19990216
     WO 2000-GB511
                             20000215
                       W
RE.CNT 8
              THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT
L3
     ANSWER 78 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
AN
     2000:443011 CAPLUS
```

EP 1144011

Α3

20020206

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,

```
Antineoplastic Agents 440. Asymmetric Synthesis and Evaluation of the
ΤI
     Combretastatin A-1 SAR Probes (1S,2S)- and (1R,2R)-1,2-Dihydroxy-
     1-(2',3'-dihydroxy-4'-methoxyphenyl)-2-(3'',4'',5''-trimethoxyphenyl)-
     Pettit, George R.; Lippert, John W., III; Herald, Delbert L.; Hamel,
ΑU
     Ernest; Pettit, Robin K.
     Cancer Research Institute and Department of Chemistry, Arizona State
CS
     University, Tempe, AZ, 85287-2404, USA
     Journal of Natural Products (2000), 63(7), 969-974
SO
     CODEN: JNPRDF; ISSN: 0163-3864
PB
     American Chemical Society
DT
     Journal
LΑ
     English
              THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE.CNT 50
              ALL CITATIONS AVAILABLE IN THE RE FORMAT
     ANSWER 79 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
L3
     2000:425859 CAPLUS
AN
DN
     133:207717
     Antineoplastic Agents. 443. Synthesis of the Cancer Cell Growth Inhibitor
TI
     Hydroxyphenstatin and Its Sodium Diphosphate Prodrug
     Pettit, George R.; Grealish, Matthew P.; Herald, Delbert L.; Boyd, Michael
ΑU
     R.; Hamel, Ernest; Pettit, Robin K.
     Cancer Research Institute and Department of Chemistry and Biochemistry,
CS
     Arizona State University, Tempe, AZ, 85287-2404, USA
     Journal of Medicinal Chemistry (2000), 43(14), 2731-2737
SO
     CODEN: JMCMAR; ISSN: 0022-2623
PB
     American Chemical Society
DT
     Journal
     English
LA
RE.CNT 32
              THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT
     ANSWER 80 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
L3
AN
     2000:401690 CAPLUS
DN
     133:48878
     Oligopeptide prodrug compounds and process for preparation thereof
TT
     Lobl, Thomas J.; Dubois, Vincent; Fernandez, Anne-Marie; Gangwar, Sanjeev;
TN
     Lewis, Evan; Nieder, Matthew H.; Trouet, Andre; Viski, Peter; Yarranton,
     Geoffrey T.
PA
     Coulter Pharmaceutical, Inc., USA
SO
     PCT Int. Appl., 125 pp.
     CODEN: PIXXD2
DT
     Patent
T.A
     English
FAN.CNT 3
     PATENT NO.
                      KIND DATE
                                           APPLICATION NO.
                                                            DATE
                            -----
                                            _____
                                                            _____
     -----
     WO 2000033888
                                           WO 1999-US30393 19991210
PI
                      A2 .
                            20000615
     WO 2000033888
                       A3
                            20011108
            AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
             CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
             IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD,
             MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
             SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
             DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
             CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     EP 1144011
                       A2
                            20011017
                                           EP 1999-967462
                                                            19991210
```

```
IE, SI, LT, LV, FI, RO
                                          JP 2000-586378
                                                          19991210
     JP 2003518000 T2 20030603
                                         US 2001-879442
                                                          20010611
                      A1
                           20021003
     US 2002142955
                           19981211
PRAI US 1998-111793P
                     Ρ.
                    P
     US 1999-119312P
                           19990208
     WO 1999-US30393 W
                           19991210
                     P
                           20000614
     US 2000-211887P
                     P
                           20010511
     US 2001-290448P
    MARPAT 133:48878
OS
    ANSWER 81 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
L3
ΑN
    2000:279432 CAPLUS
DN
    133:171912
     Combination chemotherapy with combretastatin A-4 phosphate and
ΤI
     5-fluorouracil in an experimental murine colon adenocarcinoma
     Grosios, K.; Loadman, P. M.; Swaine, D. J.; Pettit, G. R.; Bibby, M. C.
ΑU
     Clinical Oncology Unit, University of Bradford, Bradford, BD71DP, UK
CS
     Anticancer Research (2000), 20(1A), 229-233
SO
     CODEN: ANTRD4; ISSN: 0250-7005
PB
     International Institute of Anticancer Research
DT
     Journal
     English
LΑ
             THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE.CNT 15
             ALL CITATIONS AVAILABLE IN THE RE FORMAT
     ANSWER 82 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
L3
AN
     2000:56669 CAPLUS
DN
     132:303079
     In vivo and in vitro evaluation of combretastatin A-4 and its sodium
ΤI
     phosphate prodrug
     Grosios, K.; Holwell, S. E.; McGown, A. T.; Pettit, G. R.; Bibby, M. C.
ΑU
     Clinical Oncology Unit, University of Bradford, Bradford, BD7 1DP, UK
CS
     British Journal of Cancer (1999), 81(8), 1318-1327
SO
     CODEN: BJCAAI; ISSN: 0007-0920
     Churchill Livingstone
PB
DT
     Journal
     English
LA
             THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE.CNT 39
             ALL CITATIONS AVAILABLE IN THE RE FORMAT
     ANSWER 83 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
L3
     1999:451301 CAPLUS
AN
DN
     131:73507
     Preparation and formulation of combretastatin A4 prodrugs and their
TI
     trans-isomers for use as antitumor agents
     Pettit, George R.; Rhodes, Monte R.
IN
     Arizona State University, USA
PA
SO
     PCT Int. Appl., 55 pp.
     CODEN: PIXXD2
DT
     Patent
     English
FAN.CNT 1
                     KIND DATE
                                          APPLICATION NO. DATE
     PATENT NO.
                                          ______
                     ____
     -----
                     A1 19990715
                                          WO 1999-US419
                                                           19990108
PΙ
     WO 9935150
         W: CA, JP, US
         RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
            PT, SE
                           19990715
                                          CA 1999-2314238 19990108
     CA 2314238
                      AΑ
                                         EP 1999-902121
                                                           19990108
     EP 1045853
                      A1
                          20001025
         R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI
                                        JP 2000-527548 19990108
                          20020108
     JP 2002500227
                      T2
```

SO

```
PRAI US 1998-71070P
                      Р
                           19980109
     US 1998-111531P
                      Р
                           19981209
     WO 1999-US419
                      W
                           19990108
             THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE.CNT 3
             ALL CITATIONS AVAILABLE IN THE RE FORMAT
     ANSWER 84 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
L3
     1999:451177 CAPLUS
ΔN
DN
     131:73506
     Synthesis and formulation of phenstatin and related prodrugs for use as
TI
     antitumor agents
     Pettit, George R.; Toki, Brian
IN
     Arizona State University, USA
PΑ
SO
     PCT Int. Appl., 39 pp.
     CODEN: PIXXD2
DT
     Patent
     English
LA
FAN.CNT 1
                                          APPLICATION NO. DATE
     PATENT NO.
                     KIND DATE
                                          ______
                           _____
     _____
                           19990715
                                          WO 1999-US475
                                                           19990109
                      A1
PΙ
     WO 9934788
         W: CA, JP, US
         RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
            PT, SE
                           19990715
                                          CA 1999-2314510 19990109
                      AA
     CA 2314510
     EP 1045689
                      A1
                           20001025
                                          EP 1999-902133
                                                           19990109
        R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI
                                          JP 2000-527239
                                                           19990109
     JP 2002500184
                      T2
                           20020108
PRAI US 1998-70878P
                      Р
                           19980109
                            19990109
     WO 1999-US475
                      W
     MARPAT 131:73506
RE.CNT 3
              THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT
     ANSWER 85 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
L3
     1999:298062 CAPLUS
AN
DN
     131:111003
     Anti-vascular approaches to solid tumor therapy: evaluation of
TI
     combretastatin A4 phosphate
     Chaplin, D. J.; Pettit, G. R.; Hill, S. A.
ΑU
     Tumour Microcirculation Group, Gray Laboratory Cancer Research Trust,
CS
     Mount Vernon Hospital, Northwood, Middlesex, UK
     Anticancer Research (1999), 19(1A), 189-196
SO
     CODEN: ANTRD4; ISSN: 0250-7005
     International Institute of Anticancer Research
PB
DТ
     Journal
     English
LΑ
              THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE.CNT 32
              ALL CITATIONS AVAILABLE IN THE RE FORMAT
     ANSWER 86 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
L3
AN
     1999:284035 CAPLUS
DN
     131:82669
     Antineoplastic agents 393. Synthesis of the trans-isomer of combretastatin
TI
     A-4 prodrug
     Pettit, George R.; Rhodes, Monte R.; Herald, Delbert L.; Chaplin, Dai J.;
     Stratford, Michael R. L.; Hamel, Ernest; Pettit, Robin K.; Chapuis,
     Jean-Charles; Oliva, Deanna
     Cancer Research Institute and Department of Chemistry, Arizona State
CS
     University, Tempe, AZ, 85287-2494, USA
```

Anti-Cancer Drug Design (1998), 13(8), 981-993

CODEN: ACDDEA; ISSN: 0266-9536

1999:5893 CAPLUS

130:206764

AN DN

```
PB
     Oxford University Press
DT
     Journal
LΑ
     English
              THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE.CNT 12
              ALL CITATIONS AVAILABLE IN THE RE FORMAT
     ANSWER 87 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
L3
ΑN
     1999:241795 CAPLUS
     131:39356
DN
     Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early
TΙ
     effects in tumors and normal tissues
ΑU
     Tozer, Gillian M.; Prise, Vivien E.; Wilson, John; Locke, Rosalind J.;
     Vojnovic, Borivoj; Stratford, Michael R. L.; Dennis, Madeleine F.;
     Chaplin, David J.
     Tumor Microcirculation Group, Gray Laboratory Cancer Research Trust, Mount
CS
     Vernon Hospital, Northwood, HA6 2JR, UK
     Cancer Research (1999), 59(7), 1626-1634
SO
     CODEN: CNREA8; ISSN: 0008-5472
     AACR Subscription Office
PB
DT
     Journal
     English
LA
              THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE.CNT 43
              ALL CITATIONS AVAILABLE IN THE RE FORMAT
L3
     ANSWER 88 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
ΑN
     1999:222768 CAPLUS
DN
     131:31823
     Antineoplastic Agents. 410. Asymmetric Hydroxylation of
ΤI
     trans-Combretastatin A-4
     Pettit, George R.; Toki, Brian E.; Herald, Delbert L.; Boyd, Michael R.;
ΑU
     Hamel, Ernest; Pettit, Robin K.; Chapuis, J. Charles
     Cancer Research Institute and Department of Chemistry, Arizona State
CS
     University, Tempe, AZ, 85287-2404, USA
     Journal of Medicinal Chemistry (1999), 42(8), 1459-1465
SO
     CODEN: JMCMAR; ISSN: 0022-2623
     American Chemical Society
PR
     Journal
DТ
     English
LA
     CASREACT 131:31823
OS
RE.CNT 27
              THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT
L3
     ANSWER 89 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
AN
     1999:89966 CAPLUS
DN
     130:261394
TI
     Determination of combretastatin A-4 and its drug in plasma by
     high-performance liquid chromatography
ΑU
     Stratford, Michael R. L.; Dennis, Madeleine F.
CS
     Gray Laboratory Cancer Research Trust, Mount Vernon Hospital,
     Northwood/Middlesex, HA6 2JR, UK
     Journal of Chromatography, B: Biomedical Sciences and Applications (1999),
SO
     721(1), 77-85
     CODEN: JCBBEP; ISSN: 0378-4347
DΒ
     Elsevier Science B.V.
דת
     Journal
T.A
     English
RE.CNT 8
              THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT
L3
     ANSWER 90 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
```

RE.CNT 37

```
Targeting the tumor vasculature with combretastatin A-4 disodium
TI
     phosphate: effects on radiation therapy
     Li, Lingyun; Rojiani, Amyn; Siemann, Dietmar W.
AU
     Department of Pharmacology and Experimental Therapeutics, Shands Cancer
CS
     Center, University of Florida, Gainesville, FL, 32610, USA
     International Journal of Radiation Oncology, Biology, Physics (1998),
SO
     42(4), 899-903
     CODEN: IOBPD3; ISSN: 0360-3016
PR
     Elsevier Science Inc.
DT
     Journal
    English
LΑ
              THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE.CNT 20
              ALL CITATIONS AVAILABLE IN THE RE FORMAT
     ANSWER 91 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
L3
     1999:5892 CAPLUS
AN
DN
     130:231998
TΙ
     The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary
     carcinoma and a variety of murine spontaneous tumors
     Horsman, Michael R.; Ehrnrooth, Eva; Ladekarl, Morten; Overgaard, Jens
ΑU
     Danish Cancer Society, Department of Experimental Clinical Oncology,
CS
     Aarhus University Hospital, Aarhus, DK-8000, Den.
     International Journal of Radiation Oncology, Biology, Physics (1998),
SO
     42(4), 895-898
     CODEN: IOBPD3; ISSN: 0360-3016
     Elsevier Science Inc.
PB
דת
     Journal
LA
     English
              THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE.CNT 14
              ALL CITATIONS AVAILABLE IN THE RE FORMAT
L3
     ANSWER 92 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
     1999:5891 CAPLUS
AN
DN
     130:204769
     Effects of combretastatin on murine tumors monitored by 31P MRS, 1H MRS
TI
     and 1H MRI
ΑU
     Maxwell, R. J.; Pharm, B.; Nielsen, F. U.; Breidahl, T.;
     Stodkilde-Jorgensen, H.; Horsman, M. R.
     Gray Laboratory Cancer Research Trust, Northwood, HA6 2JR, UK
CS
     International Journal of Radiation Oncology, Biology, Physics (1998),
SO
     42(4), 891-894
     CODEN: IOBPD3; ISSN: 0360-3016
     Elsevier Science Inc.
PB
     Journal
DT
     English
LA
              THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE.CNT 13
              ALL CITATIONS AVAILABLE IN THE RE FORMAT
     ANSWER 93 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
L3
     1998:301433 CAPLUS
AΝ
DN
     129:36213
     Antineoplastic agents. 389. New syntheses of the combretastatin A-4
TT
     prodrug
     Pettit, George R.; Rhodes, Monte R.
AU
CS
     Cancer Research Institute and Department of Chemistry, Arizona State
     University, Tempe, AZ, 85287-2404, USA
     Anti-Cancer Drug Design (1998), 13(3), 183-191
SO
     CODEN: ACDDEA; ISSN: 0266-9536
PB
     Oxford University Press
DT
     Journal
LA
     English
```

THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD

- L3 ANSWER 94 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN AN 1998:253141 CAPLUS
- DN 128:230173
- TI Antineoplastic Agents. 379. Synthesis of Phenstatin Phosphate
- AU Pettit, George R.; Toki, Brian; Herald, Delbert L.; Verdier-Pinard, Pascal; Boyd, Michael R.; Hamel, Ernest; Pettit, Robin K.
- CS Cancer Research Institute and Department of Chemistry, Arizona State University, Tempe, AZ, 85287-1604, USA
- SO Journal of Medicinal Chemistry (1998), 41(10), 1688-1695 CODEN: JMCMAR; ISSN: 0022-2623
- PB American Chemical Society
- DT Journal
- LA English
- RE.CNT 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT
- L3 ANSWER 95 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
- AN 1997:335437 CAPLUS
- DN 127:60262
- TI Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature
- AU Dark, Graham G.; Hill, Sally A.; Prise, Vivien E.; Tozer, Gillian M.; Pettit, George R.; Chaplin, Dai J.
- CS Tumour Microcirculation Group, Gray Laboratory Cancer Research Trust, Mount Vernon Hospital, Northwood, HA6 2JR, UK
- SO Cancer Research (1997), 57(10), 1829-1834 CODEN: CNREA8; ISSN: 0008-5472
- PB American Association for Cancer Research
- DT Journal
- LA English
- RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT
- L3 ANSWER 96 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
- AN 1996:616598 CAPLUS
- DN 125:309027
- TI Combretastatin A-4 prodrug
- IN Pettit, George R.
- PA Arizona State University, USA
- SO U.S., 7 pp. CODEN: USXXAM
- DT Patent
- LA English
- FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
ΡI	US 5561122	Α	19961001	US 1994-363406	19941222
ד א מת	ITC 1001-363406		19941222		

- L3 ANSWER 97 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
- AN 1996:108637 CAPLUS
- DN 124:260682
- TI Synthesis of water-soluble prodrugs of the cytotoxic agent combretastatin A4
- AU Bedford, Simon B.; Quarterman, Charmaine P.; Rathbone, Daniel L.; Slack, John A.; Griffin, Roger J.; Stevens, Malcolm F. G.
- CS Aston Molecules Ltd., Birmingham, B7 4EJ, UK
- SO Bioorganic & Medicinal Chemistry Letters (1996), 6(2), 157-60 CODEN: BMCLE8; ISSN: 0960-894X
- PB Elsevier

WO 1992-GB498 MARPAT 118:101642

os

```
DT
     Journal
     English
LA
     ANSWER 98 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
L3
     1995:661775 CAPLUS
AN
     123:227731
DN
     Antineoplastic agents. 322. Synthesis of combretastatin A-4 prodrugs
ΤI
     Pettit, George R.; Temple, Carroll, Jr.; Narayanan, Ven L.; Varma, Ravi; Simpson, Michael J.; Boyd, Michael R.; Rener, Gregory A.; Bansal, Namita
ΑU
     Cancer Research Institute and Department of Chemistry, Arizona State
CS
     University, Temple, AZ, 85287-1604, USA
     Anti-Cancer Drug Design (1995), 10(4), 299-309
SO
     CODEN: ACDDEA; ISSN: 0266-9536
     Oxford University Press
PB
DT
     Journal
LΑ
     English
L3
     ANSWER 99 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
     1993:101642 CAPLUS
AN
     118:101642
DN
     Preparation of combretastatin A4 analogs as neoplasm inhibitors
TI
     Rathbone, Daniel Lee; Slack, John Alfred; Griffin, Roger John; Quarterman,
IN
     Charmaine Paulina
     Aston Molecules Ltd., UK
PΑ
     PCT Int. Appl., 29 pp.
SO
     CODEN: PIXXD2
DT
     Patent
LA
     English
FAN.CNT 1
                    KIND DATE
                                         APPLICATION NO. DATE
     PATENT NO.
     ______
                                           -----
PΙ
     WO 9216486 A1 19921001
                                          WO 1992-GB498
                                                           19920319
         W: AU, CA, JP, US
         RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE
                                          AU 1992-13719 19920319
     AU 9213719
                     A1 19921021
PRAI GB 1991-6177
                           19910322
                        19920319
```